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The cell infiltration into the myocardial infarction (MI) site was studied using 
magnetic resonance imaging (MRI) with micrometer-sized iron oxide particles (MPIO) as 
cell labeling probes. MI is a leading cause of global death and disability. However, the 
roles of inflammatory cells and stem cells during the post-MI remodeling and repair 
processes are yet to be discovered. This study was to develop noninvasive MRI 
techniques to monitor and quantify the cellular infiltration into the MI site. MPIO can 
produce pronounced signal attenuation at regions of interest in MRI. Therefore, cells 
labeled with these particles can be detected after they are activated and home to the MI 
site. In the first project, MPIO of various doses were injected into the mouse blood 
stream 7 days before the MI surgery. Serial MRI was performed at various time points 
post-MI to monitor the inflammatory cell infiltration into the MI site. Significant signal 
attenuation caused by labeled cells, in particular macrophages, was observed at the MI 
site. The study suggests an optimal imaging window should be from 7 to 14 days post-MI, 
during which the MR signal was inversely proportional to the MPIO dose. The study also 
suggests an optimal MPIO dose should be between 9.1 and 14.5 µg Fe/g body weight. In 
the second project, mesenchymal stem cells labeled with MPIO were transplanted into 
the mouse bone marrow 14 days before the MI surgery. Serial MRI was performed at 
various time points post-MI to monitor the labeled cells, which mobilized from the bone 
marrow and homed to the MI site. All the MRI findings were further confirmed by 
histology. In addition to revealing the characteristics of cell infiltration during MI, this 
study also provides noninvasive MRI techniques to monitor and potentially quantify 
labeled cells at the pathological site. The technique can also be used to investigate the 
function of cells engaged in MI and to test the effect on cell infiltration caused by any 











1.1 CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is one of the leading causes of death and disability 
worldwide. CVD accounts for about 16.7 million deaths, which is 29.2% of all deaths in 
the world  according to the  World Health Organization1. CVD represents a major 
economic burden on healthcare systems in developed countries2. As the number of obese 
people and aging population increase, the cost associated with CVD is likely to grow. It 
is reported that CVD accounted for 34.2% (829,072) of all deaths in the United States in 
2006 and the cost of CVD was estimated to be $475.3 billion3. Of all types of CVD, 
coronary heart disease accounted for more than 50%. Figure 1.1 illustrates the percentage 
breakdown of deaths due to CVD in the United States in 2006. 
 
Figure 1.1 Percentage breakdown of deaths due to CVD in the United States in 2006. 
Source: National Center for Health Statistics (NCHS). Numbers are rounded. Adapted 





Medical imaging plays important roles in the diagnosis and treatment of CVD. 
Many established imaging protocols have been applied to the routine clinical procedures. 
For instance, nuclear medicine imaging methods have become one of the standard 
clinical procedures to assess cardiac function. Positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) are widely used in nuclear 
medicine to detect coronary artery diseases following the injection of 
radiopharmaceuticals such as 99mTc-Sestamibi and 18fluorodeoxyglucose (FDG). Unlike 
those imaging modalities utilizing radiation, magnetic resonance imaging (MRI) 
precludes the risk to patients caused by any radiation exposure. Since MRI is able to 
achieve a better soft tissue contrast, anatomical changes caused by cardiac disease can 
thus be detected even without any administration of contrast media. For example, serial 
cardiac images (also referred as cine cardiac MRI) can be acquired at various times 
during the cardiac cycle to measure the cardiac output and ejection fraction, and 
consequently to evaluate cardiac function. Abnormalities in the ventricular wall motion 
and thickness can also be detected. Cardiac MRI becomes even more powerful with 
contrast agent enhancement. Using gadolinium-enhanced MRI to detect alteration of 
myocardial perfusion and myocardial viability caused by coronary artery diseases has 
already been established as a standard clinical procedure4-7. With the development of 
novel imaging sequences and parallel imaging techniques, MRI can achieve its 
tremendous potentials in the prognosis of cardiac coronary diseases. More information 







1.2 MYOCARDIAL INFARCTION  
Myocardial infarction (MI), also known as a heart attack, is a process of cell death 
caused by the shortage or interruption of blood supply to the affected myocardium. The 
causes can be either partial or complete occlusion of one or more coronary arteries. It is 
widely recognized that to a large extent occlusion of a coronary artery is caused by a 
thrombosis8. The thrombosis induced by rupture of a coronary atherosclerotic plaque can 
block the blood flow and thus stop the oxygen supply to the affected cardiac area.  
Following rupture of an atherosclerotic plaque, coagulating factors such as 
platelets and red blood cells aggregate in the site and form a fibrin-containing clot. If no 
collateral blood vessel develops following the obstruction, the shortage of blood flow to 
the affected myocardium causes cell death, either necrosis, apoptosis, or both. Cellular 
changes occur within 20 minutes after coronary artery occlusion, including 
phosphocreatine and creatine depletion, intracellular edema, and myocyte distortion9. 
Within the first hour of blood interruption, mitochondria swelling and nuclear chromatin 
margination are observed. Neutrophils infiltration and digestion process start within 6 
hours after occlusion. These cells release phosphorylase, endopeptidase and oxidative 
enzymes after they reach the infarction site. By 24 hours after occlusion, the myocyte 
nucleus disappears and myofibrils are stretched due to ventricular contraction. A few 
days after occlusion, macrophages migrate to the infarction site and remove the debris. 
Granulation tissue can be observed at 10 days after occlusion. Collagenization and 





As previously stated, the term myocardial infarction reflects cell death of cardiac 
myocytes caused by ischemia. Possible ischemic symptoms include various combinations 
of chest, upper extremity, jaw, or epigastric discomfort with exertion or at rest10. The 
discomfort associated with acute MI usually lasts at least 20 min. MI may be detected 
only by ECG, biomarker elevations, or cardiac imaging, with atypical symptoms or even 
without symptoms. By size, MI can be classified as microscopic (focal necrosis), small 
(<10% of the left ventricular myocardium), moderate (10-30% of the left ventricular 
myocardium), and large (>30% of the left ventricular myocardium)10. From onset of a MI 
until a scar formation, MI can be temporally breakdown into four stages: evolving (<6 hr), 
acute (6 hr–7 days), healing (7–28 days), and healed (29 days and beyond)10.  Evolving 
infarction is referred to as the stage between onset of a MI and the initiation of myocyte 
cell death. Around 6 hours after onset, polymorphonuclear leukocytes start to infiltrate 
into the MI site. The presence of these cells characterizes the stage of acute MI. Healing 
infarction is characterized by the absence of polymorphonuclear leukocytes, and the 
infiltration of mononuclear cells (MNCs) and fibroblasts. The appearance of scar tissue 
marks a healed infarction.  
Most clinical infarctions involve the left ventricle, and the right ventricular 
infarction is less common. MI can result in the damage of myocardial tissue, abnormality 
of ventricular wall motion and finally the decline of cardiac function. Due to the loss of 
myocardium, the ventricular wall at the infarction site can become as thin as a paper. The 
left ventricular ejection fraction (LVEF) can be undermined so severely that the blood 
supply cannot meet the demand, finally leading to heart failure and death. In patients with 





Other important assessments include left ventricular volume, wall thickness and valve 
function.    
Many cell types involve in the post-MI myocardial remodeling and repair 
processes. Inflammatory cells such as monocytes/macrophages home to the infarction site 
and remove the necrotic tissue debris during the healing stage (7–18 days). Stem cells 
such as messenchymal stem cells migrate to the injured site and try to repair the damaged 
myocardium. Stem cells are critical for potential myocardial tissue regeneration and 
currently are highlighted research subjects in cardiac cell therapy.     
1.2.1 Inflammatory Response in MI 
Inflammation plays a vital role in the process of post-infarction myocardial 
remodeling. Inflammatory reaction is a prerequisite for post-infarction healing and scar 
formation. Reperfusion of the infarcted myocardium is accompanied by substantial 
enhancement of inflammatory response. However, augmented inflammatory response can 
result in deleterious ventricular remodeling, ultimately leading to heart failure.  
Myocardial cell death caused by interruption of blood supply results in the 
breakdown of cellular components and membrane structures. These membrane fragments 
can trigger complement cascade and initiate the complement-mediated inflammatory 
response12,13. Myocardial cell death is also associated with an upregulation of reactive 
oxygen species, which are molecules with unpaired electrons. These reactive oxygen 
species exert direct hazard to myocardial cells. Complement activation, reactive oxygen 
species, and their mutual interaction may be involved in triggering inflammatory 





following myocardial infarction results in rapid release of tumor necrosis factor-alpha 
(TNF-), which serves as a trigger of cytokine cascade and mononuclear cell 
infiltration17,18.  
The cell-mediated inflammatory process begins with recruitment and infiltration 
of neutrophils, which may be capable of amplifying cell recruitment through release of 
oxidants and proteases19,20. Following initiation of inflammatory response, neutrophils 
migrate to the affected myocardium and rapidly change their shape as well as 
deformability, which is induced by chemotactic factors. The changes in shape and 
deformability, and interactions with endothelial cells via adhesion molecules (e.g., 
selectins and integrins) result in the adherence of neutrophils to the endothelium as well 
as the transendothelial migration into the extravascular inflamed tissue. Following ligand-
specific adhesion to myocardial cells, neutrophils can release toxic products such as 
proteolytic enzymes and reactive oxygen species, which can directly injure the 
surrounding cardiac myocytes21,22.   
Following the phase of neutrophil infiltration is mononuclear cell infiltration. 
Monocytes differentiate into macrophages after they are recruited into the infarcted 
myocardium. Although it warrants further investigation to elucidate the exact roles of the 
macrophages in the post-MI healing process, the fact that the beneficial effects of 
reperfusion accompanied by enhanced monocyte infiltration suggests that macrophages 
may promote the effective myocardial repair23,24. Macrophages and mast cells may be 
capable of supporting fibrosis and neovacularization by secreting cytokines and growth 
factors25,26,27, however, a clear definition of their roles requires further investigations.  





healing process by modulating mononuclear cell phenotypes28. Recruitment and 
infiltration of mast cells, monocytes/macrophages, and lymphocytes form a unique 
environment rich in inflammatory cells, which play indispensible roles in debris 
clearance, fibrosis, neovascularization and extracellular matrix remodeling. In addition to 
being a major component of regulating scar formation, fibroblasts also support 
neovascularization, which can bring oxygen and nutrients to the healing myocardium29-32.        
The inflammatory response is the key in the post-MI remodeling and repair 
process, and thus is determinant for the patient outcome33. Augment of pro-inflammatory 
cytokine cascades can result in the deterioration of left ventricular function. Therefore, 
modulation of the pro-inflammatory cytokine cascades can potentially reverse the 
downfall of left ventricular function34. This type of approaches are usually called anti-
inflammatory strategies, which have been used in the treatment of MI35-37. For instance, 
angiotensin-converting-enzyme inhibitors (ACE-Is) have demonstrated efficacy in 
preventing deterioration of left ventricular function, partially due to their anti-
inflammatory effects on reducing the expression of pro-inflammatory cytokines38,39. 
Statin (or HMG CoA reductase inhibitors) is another class of anti-inflammatory drugs 
used to ameliorate post-MI cardiac function40,41. However, it is still open to debate 
whether or not it is the anti-inflammatory mechanism that causes cardiac function 
improvement and how the mechanism works34,42. Apparently, a better understanding of 
molecular interactions and inflammatory mechanisms involved in the MI is needed in 
order to develop effective and specific therapeutic strategies that can minimize 






1.2.2 Roles of Monocytes/Macrophages in MI 
After MI, occlusion of a coronary artery jeopardizes the affected myocardium and 
induces myocardial cell death due to diminished or obstructed blood oxygen supply. The 
cell necrosis triggers the inflammatory process through release of cytokines and 
chemokines. During the inflammatory process, circulating monocytes respond to the 
chemotactic signals, migrate into the infarction site and differentiate into macrophages. 
The macrophages play many pivotal roles during the myocardial remodeling. At the 
infarction site, for example, the macrophages clear necrotic myocytes and apoptotic 
neutrophils; they also secrete cytokines, chemokines and growth factors which contribute 
to inflammation cascade and regulate multiple healing events such as scar formation and 
angiogenesis27. The inflammatory response is essential for post-MI ventricular 
remodeling and the roles of macrophages are of fundamental importance in this process. 
The primary functions of macrophages are listed in Table 1.1.  
 
 
Table 1.1 Primary functions of macrophages 
Function Role post-MI 
Phagocytosis Remove necrotic myocytes and apoptotic neutrophils 
Chemotaxis Recruit additional macrophages to injury site to amplify response 
Secretion Regulate scar formation by secreting growth factors, angiogenic 
factors, and matrix metalloproteinases 
Angiogenesis Restore blood flow 











1.2.3 Roles of Stem Cells in MI 
Apart from macrophages, stem cells may also play fairly important roles in the 
post-MI repair mechanism43. In the adult heart, cardiac myocytes enter into a post-mitotic 
state and lose the capability of proliferation and differentiation. In the condition of MI, 
cardiomyocytes would enlarge to compensate for the declined cardiac function rather 
than proliferate to repair the damaged tissue. An estimated 10-40% of MI patients are 
likely to develop heart failure, since the scar tissue healing over the necrosed 
myocardium contains mononuclear and fibroblast cells, but rare contractile or pacemaker 
myocytes10,44. The lack of cardiomyocyte progenitors limits the capability of the heart to 
regenerate itself.  
Current therapeutic approaches are constrained by the fact that an adult heart has 
a limited capacity of regeneration, and thus concentrated at slowing disease progression 
instead of repairing the damaged tissue and restoring cardiac function. The goal of 
finding a once-and-for-all solution for MI motivates scientists and cardiologists to 
investigate alternative therapeutic strategies. As a promising alternative, stem cell therapy 
has recently been widely explored, attempting to regenerate myocardial tissue at the MI 
site and impede heart failure development. The exact roles of stem cells in the myocardial 
repair and remodeling processes are not well understood and clinical studies have 
produced mixed results45,46. However, in vitro cell culture and animal experiments have 
yielded exciting results after stem cells were transplanted into the infarcted heart. 
Whereas there is a wide debate about whether stem cells can engraft to and couple with 
the myocardium and improve cardiac function, clearly more efforts are warranted before 





Many cell types such as embryonic stem cells (ESC)47, human ESC-derived 
cardiomyocytes48, skeletal myocytes49, and bone marrow-derived stem cells50,51 have 
been transplanted into the infarcted myocardium in both animal and human models to 
determine their beneficial effects. However, complications have occurred when 
embedding these cells into the myocardium. For example, ESC may cause an adverse 
immunological response and/or teratoma formation52; successful differentiation of human 
ESC-derived cardiomyocytes involves a highly complex process not easily performed53; 
and engrafted skeletal myocytes may fail to functionally integrate with the host tissue54. 
Mesenchymal stem cells (MSC) may be a better therapeutic option since they exhibit a 
multi-lineage plasticity, a reduced immune response, and are easy to harvest55,56. Previous 
research by Quevedo et al57 showed that MSC were capable of restoring cardiac function  
via trilineage differentiating capacity. Table 1.2 summarizes many potential cell types as 
well as their respective advantages and disadvantages for MI cell therapy. Table 1.3 
summarizes some recent clinical trials using bone marrow-derived cell transplantation for 
treating acute MI. The outcomes were mixed and the exact roles that stem cells play in 
post-MI remodeling are yet to be discovered. 
How stem cells or progenitor cells mediate the post-MI repair process and 
consequently improve cardiac function is still unknown. While some types of stem cells 
may have potential of regenerating the myocardium, they may also contribute to 
myocardial repair via neovascularization58,59 and modulation of inflammatory 
response60,61. Ciulla et al demonstrated that bone marrow MNCs selectively homed to the 
injured myocardium and contributed to the vessel formation58. Kawamoto et al showed 





significantly enhanced neovascularization in the myocardial ischemia59. Ciulla et al 
investigated the effects of bone marrow MNC therapy on pro-inflammatory cytokines 
and on left ventricle remodeling, and compared these effects over a standard ACE-I 
therapy in a rat model of myocardial injury. They found that both bone marrow MNCs 
and ACE-I reduced the expression of pro-inflammatory cytokines and contributed to the 








Table 1.2 Advantages and disadvantages of potential cell types for MI cell therapy 
Cell types Advantages Disadvantages 
Fetal/neonatal 
cardiomyocytes 
 Establish E-M 
coupling 
 High proliferative 
capacity 
 Genetic engineering 
 Ethical/moral issues 
 Donor availability 
 Poor long-term 
survivability 
 Immune rejection 
 Sensitive to ischemic 
injury 
Embryonic stem cells 
 Pluripotent 
 Establish E-M 
coupling 
 Genetic engineering 
 Ethical/moral issues 
 Difficult scalability  





 Ease of isolation and 
culture scalability 
 Autologous source 
 Ischemia resistance 
 Genetic engineering 
 Inability to establish 
E-M coupling 





 Ease of isolation and 
culture scalability 
 Autologous source 
 Genetic engineering 
 Insufficient 
characterization 
Bone marrow derived 
mesenchymal stem cells 
 Multipotent 
 Ease of culture and 
isolation 
 Autologous source 
 Genetic engineering 
 Difficult scalability 
 Deficient 
characterization 
Smooth muscle cells 
 Ease of isolation and 
culture scalability 
 Secrete angiogenic 
factor 
 Autologous source 
 Inability to establish 
E-M coupling 
 Potential arrhythmias 









Table 1.3 Randomized clinical trials using bone marrow-derived cell transplantation for 
acute MI treatment 






Strauer63 MNC 5–9 
Regional wall motion, 






5 ± 2 
Regional wall motion, 
LVEF, infarct size 
LVEDV 
Wollert65 MNC 6 ± 1 
Regional wall motion, 
LVEF, infarct size 
LVEDV, 
infarct size 
Chen66 MSC 18 
Regional wall motion, 
LVEF, LVEDV 
NA 
Bartunek67 CD133+ 11.6 ± 1.4 
Regional wall motion, 
LVEF, infarct size 
NA 
Janssens68 MNC 1 




Lunde69 MNC 4–6 NA 
LVEF, 
infarct size 




Note: LVEDV: left ventricular end-diastolic volume; EPC: endothelial progenitor cells; 


















1.3 CARDIAC IMAGING MODALITIES 
Previously, electrocardiogram (ECG) and coronary catheterization (also called 
coronary angiography) have been the primary methodologies for the diagnosis and 
prognosis of cardiovascular disease. However, the limited sensitivity of ECG, and the 
poor regional resolution and invasive nature of coronary catheterization necessitate the 
development of additional imaging techniques that can simultaneously provide 
complementary information on heart anatomy, cardiac function, and myocardial 
perfusion and viability. Echocardiography is able to provide more anatomic information 
which can reflect changes in cardiac tissue structure as well as wall motion. Furthermore, 
SPECT and PET have been established as functional imaging tools well suited for 
diagnosis of cardiovascular diseases. Nuclear cardiac stress testing has become a routine 
clinical procedure to detect coronary artery diseases and to prevent further morbidity or 
mortality. Since the 1970s, dramatic advances have occurred in imaging technology, such 
as in design of radiation detectors and superconductive magnets, driving the tremendous 
evolution in computed tomography (CT) and MRI technology. At present, CT and MRI 
are being used increasingly for routine diagnosis and prognosis. Along with PET, SPECT 
and echocardiography, CT and MRI have become the major imaging methodologies for 
cardiovascular diagnosis.      
1.3.1 Echocardiography 
Echocardiography has made a significant contribution to the evolution of cardiac 
imaging as a noninvasive, convenient and inexpensive imaging methodology. 
Echocardiography is a simple, widely accessible technique for evaluation of ventricular 





The advantages of echocardiography lie in its high temporal resolution, simplicity and 
bedside portability.  
Echocardiography is widely used in the measurement of ventricular blood flow 
velocities, and cardiac tissue velocities and stains. In this manner, echocardiography has 
been used in the diagnosis of left ventricular dissynchrony71, characterization of the 
myocardial scar tissue72, evaluation of hypertrophic cardiomyopathy73, and assessment of 
valve dysfunction74. However, applications of echocardiography in cardiac imaging are 
limited by its inherent shortcomings: poor image quality, lack of detailed anatomic 
information and consequently difficulty in interpretation. While some new techniques in 
echocardiography including contrast enhancement and three-dimensional 
echocardiography are now under development and have potential in supporting its 
position in cardiac imaging75, many of its roles are now filled by other imaging 
modalities such as PET, CT and MRI.          
1.3.2 CT 
The enormous advancement in CT technology has tremendously enhanced both 
temporal and spatial resolution of modern CT systems. CT systems have evolved rapidly 
from single-slice to multi-slice imaging (64-slice systems are now available in routine 
diagnosis), allowing acquisition of a three-dimensional data set in a few seconds. In 
addition, improved spatial resolution renders much better visualization and more accurate 
quantitative analysis. The increased temporal resolution enables the gantry to finish one 
rotation in tenths of a second, significantly reducing the artifact caused by the motion of 





voxel as small as 0.5x0.5x0.5 mm3, which is feasible to visualize and diagnose the 
coronary arteries.  
Recently, CT has been used to define the cardiac anatomy76, evaluate cardiac 
function77,78 and image the great vessels as well as coronary arteries79,80. Since CT 
imaging is based on the detection of transmitted x-ray through the human body, the best 
contrast is achieved between soft tissue and targets of interest with a relatively high 
atomic number. In this manner, CT is a superb modality for differentiation of coronary 
calcification81,82. Similarly, CT angiography can provide well defined images of blood-
containing structures including atria, ventricles and blood vessels, following injection of 
the iodinated contrast media.             
However, the principle of utilizing radiation to reconstruct the images 
unavoidably creates a potential hazard to patients. Recently, the relatively high dose in 
CT imaging has drawn intensive concern. For instance, coronary CT angiography 
engages continuous radiation exposure and thus can lead to a considerably high dose83. 
Table 1.4 presents some common CT procedures and their corresponding patient dose.  
Furthermore, CT does not have soft tissue contrast as good as that obtained from MRI. A 
relatively large radiation dose is required in order to achieve sufficient soft tissue contrast, 
which could result in significant radiation exposure to the patient. CT also faces 
challenges when it is used to evaluate cardiac function and quantify heart parameters. The 
large dose caused by the continuous radiation exposure during cardiac loops greatly 
restricts the application of functional CT to patients. Neither is CT a good option of 
performing repeatable longitudinal diagnosis, which otherwise would result in a 





Table 1.4 Effective dose and background equivalent years for diagnostic coronary 
angiograms and selected CT examinations. 
CT procedures Effective dose (mSv) 
Background equivalent 
years 
Coronary angiogram 3-25 1-7 
Coronary CTA 7-13 2-4 
Prospective CACS 1.5-3.6 0.4-1 
Chest CT 5-7 1.4-4 
Abdomen/pelvis CT 8-11 2-3 
Average US annual background 3.6  1 
Note: the average annual background includes medical exposure. CTA: CT angiography; 




1.3.3 PET and SPECT 
Nuclear medicine has been well established as a routine methodology for 
diagnosis and prognosis of coronary artery diseases. The biochemical environment of 
cardiac tissue changes when the heart undergoes a pathological condition, which results 
in a discontinuous distribution of radiopharmaceuticals in the myocardium. Nuclear 
medicine techniques are sensitive to detect the reduced concentration of 
radiopharmaceuticals caused by decreased myocardial perfusion/metabolism and 
consequently to identify the regions undergoing coronary artery diseases. The prognosis 
of ischemic cardiac diseases is based on the extent of myocardial ischemia and the degree 
of ventricular remodeling. SPECT and PET can provide information on myocardial 
metabolism, perfusion and cardiac function simultaneously, and thus are well suited for 
studying cardiac ischemic diseases84.   
The advent of numerous radiopharmaceuticals has contributed significantly to the 
extensive use of PET and SPECT in cardiology and the maturation of nuclear medicine 





196485. At the present time, three 99mTc-labeled tracers have been approved by the United 
States Food and Drug Administration (FDA): Sestamibi, Teboroxime and Tetrofosmin86. 
99mTc has advantages compared with its predecessor 201Tl, which has a low energy 
spectrum and long physical half life. Two positron emitters, 13N and 82Rb, are commonly 
used in PET imaging. The characteristics of common radiopharmaceutical are presented 
in Table 1.5. Following injection of radiopharmaceuticals, PET and SPECT are used in 
the diagnosis and prognosis of cardiovascular diseases to assess cardiac parameters such 
as ejection fraction and wall motion87, examine myocardial viability and perfusion88, and 
estimate the extent of ischemia89.  However, the diagnosis efficacy of nuclear medicine 
techniques is limited by their low spatial resolution, which is especially true for SPECT 
due to the poor correction of photon attenuation and scattering. In addition, each nuclear 
medicine procedure requires an administration of radiopharmaceuticals which accumulate 
not only in the heart but also in other healthy organs such as brain and bladder and thus 
inevitably expose the patient to radiation risk.   
 
 








Time to imaging 
from injection 




296-1480 140 15-45 min 6 hrs 
PET 82Rb 1110-2220 511 80 sec 75 sec 
 13N-Ammonia 370-740 511 6 min 10 min 










In the past decades, tremendous advances in the field of nuclear magnetic 
resonance have taken place. In hardware, a superconductive magnet that can provide as 
high as seven Tesla is common now for the purpose of translational studies. Three-Tesla 
MRI systems are now commonly used in routine clinical diagnosis. Including design of 
more efficient radio frequency (RF) and gradient coils as well as development of more 
specific contrast agents, all these innovations have dramatically improved the quality of 
MRI images. Furthermore, the development of parallel imaging and design of new 
imaging sequences allow cardiac image acquisition to occur within just a couple of heart 
beats, which dramatically improves the temporal resolution. In addition, the intensive 
research efforts and promising outcomes in cardiac magnetic resonance spectroscopy 
(MRS) can potentially translate this quantitative imaging method from benchside to 
bedside, leading to more accurate diagnosis and prognosis in the future.             
MRI can provide cardiac images with high quality and reproducibility, which 
makes it a standard reference in the display of cardiac anatomy and measurement of 
ventricular function. Cardiac MRI has been accepted as a competitive or even superb 
methodology in the detection of myocardium viability and diagnosis of coronary artery 
diseases compared with echocardiography and nuclear medicine90-92. Gadolinium-
enhanced MRI has been widely used in the diagnosis of myocardial infarction. 
Hypoperfused myocardium in coronary artery disease can be visualized by using first-
pass gadolinium-enhanced MRI93. Bertschinger et al94 demonstrated that first-pass 
gadolinium-enhanced MRI can not only delineate the perfusion defect due to coronary 





Myocardium viability can be detected and assessed with late gadolinium-enhanced MRI. 
The high image quality and sufficient contrast by gadolinium enhancement enable 
cardiac MRI to provide an accurate estimation of the location, extent and detailed 
distribution of the viable myocardium95,96.  
MRI has improved spatial resolution compared with other modalities. The high 
resolution allows cardiac MRI not only to differentiate the perfusion-defective 
myocardium from normal myocardium, and distinguish viable from nonviable 
myocardium, but to disclose the transmural extent of the MI. As mentioned earlier, the 
poor image quality of echocardiography results in 15% of echocardiographic images 
being suboptimal or nondiagnostic92. Nuclear medicine modalities are limited either by 
the lack of photon attenuation correction in SPECT, or by high cost for PET diagnosis. In 
addition, both PET and SPECT involve radiation exposure to patients. Another advantage 
of MRI is its flexibility in localization of an imaging plane in two-dimensional imaging. 
In MRI an image plane can be set in an arbitrary direction because choosing an imaging 
plane is achieved solely by changing the magnetic field gradient. This is important in 
cardiac MRI because the human heart is in an oblique direction, and transverse imaging 
slices are commonly interpreted. These factors make MRI a superior cardiac imaging 
modality for repeated imaging in diagnosis, prognosis and monitoring effects of 
therapeutic interventions. However, it is worth noting that the outcome of contrast-
enhanced cardiac MRI is strongly dependent on the parameters of sequences applied. In 
addition, it is occasionally necessary to make correction for the signal attenuation 
resulted from increased distance to the RF coil. Another potential drawback of MRI is the 





1.3.5 Hybrid Systems 
Each modality has its own advantages and disadvantages and therefore plays a 
unique role in the diagnosis and prognosis of cardiovascular diseases. Table 1.6 presents 
a summary of common applications of the four imaging modalities described above. 
Patients usually go through multiple rather than a single imaging modality, which 
provides complementary information and improves the efficacy and accuracy of 
diagnosis. Recently, hybrid systems physically integrating two imaging modalities have 
been developed and applied, allowing acquisition of spatially registered images 
simultaneously. At present, PET/CT and SPECT/CT are very common in the diagnosis of 
cardiovascular disease. CT provides high resolution images of coronary anatomy, and at 
the same time, PET or SPECT identifies the physiological consequences of abnormalities 
in specific coronary arteries. On the other hand, the anatomic information acquired from 
CT can be used to compute the attenuation map for PET/SPECT. Now hybrid systems 
integrating PET and MRI are also available in the market. In addition to its independent 
imaging capabilities, MRI also fills the role of providing anatomy for PET in PET/MRI 
as CT does in PET/CT.        
 
 










Catheterization Yes Yes No Yes Yes 
Echocardiography Yes No Yes No No 
PET, SPECT Yes No Yes No Yes 
CT Yes Yes Yes No Yes 






1.4 MOLECULAR MRI AND CONTRAST AGENTS 
Molecular imaging uses noninvasive, repeatable imaging methods to monitor the 
in vivo biological processes under normal or pathological conditions. The imaging 
modalities usually include optical imaging, nuclear medicine and MRI. Molecular 
imaging has been advanced by the advent of target-specific imaging probes. For example, 
fluorescent and bioluminescent proteins have been widely used in optical imaging as 
reporter genes to target interested cell lines, and FDG in PET to target the enzyme 
metabolism. Recently, the potential of MRI for molecular imaging has been extensively 
explored, with a large number of imaging probes designed, tested and applied. These 
magnetic resonance (MR) contrast agents are able to increase (positive contrast agents) or 
decrease (negative contrast agents) signal intensity by altering tissue relaxation times T1 
and/or T2. Hence, an improved image contrast between targeted tissue and background 
can be achieved.  
As a non-radiation imaging approach, MRI is a powerful tool for imaging 
morphological and functional changes due to its high spatial and temporal resolution. In 
molecular imaging, the sensitivity of MRI can be further increased by using contrast 
agents that can recognize and adhere to specific targets. The MR contrast agents are 
usually separated into two categories: paramagnetic contrast agents and 
superparamagnetic contrast agents. Whereas paramagnetic contrast agents primarily 
shorten T1 and thus result in a brighter signal in the target, superparamagnetic contrast 
agents primarily shorten T2 and thus lead to signal attenuation in the target.  Table 1.7 







Table 1.7 Properties of MR contrast agents 
Comparison Paramagnetic Superparamagnetic 
T1 Effect Strong Weak 
T2 Effect Weak Strong 
Signal intensity Increase Decrease 
MR Sequence T1-weighted T2-weighted 
Example Gadolinium chelates Iron oxide particles 
          
 
 
Paramagnetic contrast agents are based on metal ions such as gadolinium (Gd3+), 
manganese (Mn2+) or europium (Eu3+), that have a relatively large number of unpaired 
electrons. The unpaired electrons have a permanent magnetic moment. In aqueous 
solution, the electronic magnetic moment interacts with the magnetic moment of the 
nearby protons in water molecules. Random fluctuations of these dipolar interactions 
resulted from molecular motions reduce both the T1 and T2 relaxation times of the water 
protons97. The primary effect of paramagnetic contrast agents is to reduce T1, and thus 
paramagnetic contrast agents are also called T1 contrast agents. Paramagnetic metals are 
used in the form of chelates, which are complexes binding metal irons to ligands. The 
most commonly used clinical paramagnetic contrast agent is gadolinium chelates such as 
gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA). Using chelates instead of 
free metal irons can reduce the toxicity of free irons and enhance the selective targeting 
to the tissue of interest.  
Superparamagnetic contrast agents are small magnetic particles containing iron, 
and are also referred to as superparamagnetic iron oxide particles (SPIO). The atomic 





SPIO consist of iron oxide crystals coated with polymeric matrix such as dextrin and 
polymer. SPIO primarily reduce T2 relaxation time and thus are also called T2 contrast 
agents. The widespread use of SPIO is partially due to their T2
* effect. The T2
* effect 
includes not only the decay of the transverse magnetic moment due to spin-spin 
interactions (T2 relaxation), but the dephase caused by the inhomogeneity of the local 
magnetic field. The active components producing T2 or T2
* shortening effect in SPIO are 
iron oxide crystals. Each crystal contains multiple magnetic domains composed of either 
Fe2O3 or Fe3O4. The interactions of unpaired electrons in ferric and/or ferrous ion produce 
a magnetic moment for each magnetic domain. In the absence of a magnetic field, the 
magnetic moment of each magnetic domain is randomly distributed, leading to a net 
magnetic moment of zero. When an external magnetic field is applied, all the magnetic 
moments are forced to reorient and line up with the magnetic field, producing a magnetic 
field which is stronger than the simple algebraic summation of overall magnetic moments. 
This magnetic susceptibility is strong enough to disturb the local magnetic field during 
signal acquisition and cause inhomogeneity in the local magnetic field, shortening T2
 and 
T2
* values and leading to signal attenuation in T2
 or T2
* weighted MRI. Figure 1.2 
illustrates the SPIO structure and reorientation of magnetic moments when an external 
magnetic field is applied.            
 
 
Table 1.8 Electron configurations of metal ions used for contrast agents 
Metal ion Electron configuration Unpaired electrons 
Gd3+ [Xe] 6s04f75d0 7 
Mn2+ [Ar] 4s03d5 4 
Fe2+ [Ar] 4s03d6 5 





SPIO have a better biocompatibility compared to paramagnetic contrast agents. 
Gadolinium or manganese chelates distribute through the intravascular and extracellular 
space following their intravenous administration. A typical dose of 0.1–0.3 mmol/kg 
body weight is usually injected into patients in order to achieve a sufficient image 
contrast. This dose can lead to a relatively high concentration of gadolinium in the 
normal tissue. The requirement of relatively high concentration can also result in an 
osmolarity higher than that of the normal blood, which is particularly true for the ionic 
chelates97. The high osmolarity can create potential adverse effects for patients. In 
contrast, iron is a composition of the human body with abundance much higher than 
gadolinium or manganese. Iron exists in the human body in the form of haemosiderin, 
ferritin and transferrin. Normal liver contains approximately 0.2 mg Fe/gram and total 
iron store in the human body is as large as 3500 mg. The total amount of iron oxide for 
diagnostic MRI is about 50–100 mg, which is small compared to the normal iron store in 
the human body98. Chronic iron toxicity develops only after the iron concentration in the 
liver exceeds 4 mg Fe/gram99. Due to the strong superparamagnetic property of iron, 
usually a small iron dose is needed to achieve a sufficient image contrast, compared to 
gadolinium agents100. Therefore, SPIO agents are better suited for repeated measurements 









Figure 1.2 Structure of a single crystal of superparamagnetic iron oxide particles. A. 
Magnetic moments of individual domains are randomly oriented in the absence of an 
external field. B. Magnetic moments are reoriented and aligned with the magnetic field 







1.5 SPIO-ENHANCED MRI 
According to the literature101,102, iron oxide particles can be sized into four 
categories: micrometer-sized iron oxide particles (MPIO) have a diameter on the order of 
m; standard SPIO (SSPIO) have a diameter of sub-micrometer but greater than 60 nm; 
ultrasmall SPIO (USPIO) of ~10-40 nm; and monocrystalline iron oxide nanoparticles 
(MION) of ~10-30 nm. Some literatures classify particles larger than 300 nm as oral 
SPIO due to their clinical applications in imaging the gastrointestinal system, during 
which particles are orally administered. The applications of MPIO as cell labeling probes 
are now being widely explored103,104. The preparation parameters such as size, coating 
and receptor or antibody conjugation, if any, determine the specialized applications of 
SPIO.  
Generally, SPIO can work either as blood pool agents or as cellular and molecular 
agents. The low toxicity is an advantage of SPIO as a blood pool agent over other 
contrast media. The long circulating time in blood makes USPIO an effective blood pool 
agent. On one hand, USPIO have been widely applied in MR angiography for delineation 
of ventricular blood105 and enhancement of blood vessels106,107. On the other hand, 
USPIO also act as a suitable candidate for perfusion imaging and have been applied in 
the brain108, heart109 and kidney110 to differentiate the region with normal perfusion from 
those with abnormal perfusion. USPIO can also be used to characterize the abnormal 
vascularity in tumor angiogenesis111.  
Another burgeoning field is the application of SPIO as cell labeling probes in 





targeting and active targeting. SPIO passive targeting is based on the fact that SPIO can 
be phagocytized by those cell types in the reticuloendothelial system (RES), such as 
macrophages and lymphocytes. In this manner, SPIO can be used to differentiate the 
pathological tissue containing an altered quantity of RES cells from the normal tissue in 
the liver112, spleen113, bone marrow114 and lymph nodes115, particularly for tumor 
diagnosis. Furthermore, SPIO have been widely used in inflammation imaging to detect 
inflammatory activities in the brain116 and heart117. Passive targeting can also be used to 
label stem cells through the incubation of cells with SPIO. The labeled cells can be 
monitored after they are transplanted into the imaging subject118,119. Active targeting 
refers to cell labeling methods via the conjugation of SPIO with gene reporters or 
antibodies. By combining SPIO with gene markers that closely relate to a specific disease, 
the biologically engineered probes can specifically target a disease. Many cellular and 
molecular markers have been explored and tested in combination with SPIO, such as for 
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CHAPTER 2  
MONITORING INFLAMMATORY CELL INFILTRATION  





The potential of MRI as a noninvasive tool to detect contrast agent-labeled cells 
has been investigated recently, with the advent of novel contrast agents and cell labeling 
techniques1,2. As a negative enhancement contrast agent, iron oxide particles cause signal 
attenuation in T2- and T2
*-weighted images which makes them useful in a variety of 
animal models for cellular imaging3. Sized from large to small, SPIO are categorized as 
MPIO, SSPIO, USPIO and MION, respectively4. The majority of iron oxide particles 
accumulate in the liver, spleen, bone marrow and lymphatic node tissue after injection3,5,6. 
The physicochemical characteristics of iron oxide particles determine their MRI efficacy, 
blood pool kinetics, biodistribution, and metabolism within the imaged subjects7,8. Iron 
oxide contrast has been used to detect hepatic tumors9,10 and lymph node metastases11,12, 
and also for tracking stem cells13 and monitoring various diseases associated with high 
macrophage activity14,15. Recently, MPIO were shown to significantly improve cellular 
imaging when single cells loaded with single MPIO were detected via MRI16. In contrast, 
accumulation of a considerable number of USPIO in one cell was required to achieve 
sufficient image contrast. Furthermore, the dilution effect caused by cell division more 
readily leads to loss of cell tracking in USPIO cell labeling than in MPIO cell labeling.  
Inflammatory cells, in particular macrophages, are capable of taking up iron oxide 






weighted MRI during the inflammation process. In this manner, the iron oxide particles 
have been used to detect ischemia-associated inflammation18,19, macrophage-rich 
atherosclerosis20,21, and acute cardiac graft rejection22. Several pathways have been 
proposed for transporting iron oxide particles to macrophages3. For example, iron oxide 
particles could be endocytosed by activated blood monocytes migrating into affected 
tissue or they could be transcytosed across the endothelium via progressive endocytosis 
by in situ macrophages. Both mechanisms may take place simultaneously when iron 
oxide particles are transported into the affected tissue via the inflammatory 
neovasculature.  
Recently, iron oxide particles have been used to label inflammatory cells engaged 
in MI-induced cardiac tissue inflammation. Furthermore, Sosnovik and colleagues23 
demonstrated that inflammatory cells could be labeled by intravenous injection of iron 
oxide particles after the MI. In this manner, both circulating and resident inflammatory 
cells will engulf iron oxide particles and contribute to the signal attenuation around the 
MI site. Although inflammatory cells such as macrophages could also be labeled in vitro 
and then transplanted into the infarcted heart24, the transplantation delivery is usually 
limited by a low engraftment. Therefore, this study demonstrates a new cell labeling 
method for studying the inflammation process during cardiac remodeling in which the 
inflammatory cells are pre-labeled prior to the MI via intravenous injection of iron oxide 
particles.    
One purpose of this study is to investigate the temporal relationship between 
inflammatory cell infiltration and cardiac performance during MI-induced cardiac 





occurs when monocyte-derived macrophages and mast cells produce cytokines and 
growth factors necessary for fibroblast proliferation and neovascularization25. However, 
when augmented macrophage homing and cytokine production cause adverse left 
ventricular remodeling, the deterioration of cardiac function typically leads to heart 
failure26. Therefore, an advanced MRI cell tracking technique demonstrating a 
prospective for studying the in vivo behavior of inflammatory cells would help to better 
understand MI-induced inflammation.  
2.2 METHODS 
2.2.1 Animal Preparation 
Adult male C57Bl/6 mice (n=27; 23.8±1.4 g; 6–11 weeks old) were used in 
compliance with the Institutional Animal Care and Use Committee at the Medical 
College of Georgia, Augusta, GA, USA. The animals were anesthetized with a mixture of 
medical air, oxygen (1:1), and 2.0% isoflurane (Abbott Laboratories, Abbott Park, IL, 
USA), then put in a prone position on the animal cradle. The isoflurane was maintained at 
1.8±0.2% throughout all MRI sessions. This protocol maintained a constant respiration 
rate of 63±6 breaths per minute and heart rate of 437±58 beats per minute during each 
MRI session. 
The animals were divided into three experimental groups: 1) myocardial 
infarction group with MPIO injection (MI+MPIO, n=7); 2) myocardial infarction group 
without MPIO injection (MI-MPIO, n=6); and 3) sham-operated group with MPIO 
injection (Sham+MPIO, n=7). For the MI+MPIO and Sham+MPIO groups, the animals 





days post-MPIO injection, the MI+MPIO group underwent a thoracotomy (open-chest) 
surgical procedure followed by permanent ligation of the left anterior descending 
coronary artery, which induced a MI. The Sham+MPIO group underwent only the 
thoracotomy surgery, which did not cause any type of myocardial injury. This study 
investigated MPIO-labeled inflammatory cells migrating to the MI site. Therefore, none 
of the surgeries were performed until the free MPIO were cleared from the blood pool for 
both MPIO injection groups. The 7-day interval between the MPIO injection and surgical 
procedure allowed the particles to be cleared from the blood pool under the detectable 
level, which minimized potential signal attenuation contributed by circulating particles 
otherwise remaining in the blood pool. This protocol also reduced the possibility of 
activated resident inflammatory cells endocytosing the MPIO directly from the blood 
pool following the MI. 
2.2.2 Contrast Agent 
The iron oxide contrast agent used in this study was Bangs particles (a type of 
MPIO, Catalog code: ME03F; Bangs Laboratories, Inc., Fishers, IN, USA). The Bangs 
particles have a mean diameter of 1.63 µm, with a magnetite core (42.5% weight) coated 
with a polymer (P(S/V-COOH)Mag/Encapsulated). These particles are also tagged with a 
fluorescent dye (Suncoast Yellow fluorescence, excitation:emission = 540:600 nm). The 
undiluted MPIO solution (original concentration of 2.793x109 particles per ml) was 







2.2.3 Blood Sample Measurement 
MPIO blood kinetics in the murine model was examined to determine the proper 
timing for surgically inducing an experimental MI without residual effects of the negative 
MRI enhancement from the circulating iron particles. The kinetics study was performed 
on 7 non-injured animals (25.3±3.4 g; 6-12 weeks old). Blood samples were obtained at 
various times up to 8 minutes post-MPIO injection with MPIO fluorescence intensity 
measured on a 2-D IVIS 100 Imaging System (Caliper Life Sciences, Hopkinton, MA, 
USA). One or two blood samples were taken from each mouse anesthetized with 1.0% 
isoflurane. Briefly, a 27-gauge needle, 1-ml syringe and 0.5-ml tube were used and 
moistened with heparin. Then approximately 100 µl of blood was removed by puncturing 
the needle into the left ventricle of the heart. A 50-µl blood sample was then placed into 
the 96-well plate for fluorescence imaging. 
2.2.4 MI 
Animals were anesthetized with an intraperitoneal injection of ketamine/xylazine 
and placed in a supine position. A midline cervical incision was made for tracheal 
intubation. The intubated mice were then connected to a rodent ventilator (CWE Inc., 
Ardmore, PA, USA) and ventilated at a respiratory rate of 90 breaths per minute. A mid-
line thoracotomy was done to open the chest at the upper sternum between the fourth and 
fifth ribs. A MI was produced by permanently ligating the left anterior descending 
coronary artery at a position approximately 1 mm below the left auricle with an 8-0 
polypropylene monofilament suture. This coronary artery ligation caused a visual area of 
infarction in the left ventricle, seen as the tissue turning a pale color below the ligation 





left anterior descending artery was not performed on these animals. After surgery, the 
mice were allowed to recover in a recovery chamber at 38 ºC under careful supervision, 
then returned to their cages to rest until time for each imaging session. 
2.2.5 MRI 
MRI was performed one day before surgery as a baseline, and then repeated at 3, 
7 and 14 days after surgery. Images were acquired on a horizontal 7.0-T, 21-cm MRI 
spectrometer (Bruker Instruments, Billerica, MA, USA) equipped with a micro-imaging 
gradient insert (950 mT/m).  A 35mm inner diameter volume coil was used to transmit 
and receive at 1H frequency (300 MHz). The ECG and respiratory signals were monitored 
and used for gating by a physiological monitoring system (SA Instruments, INC., Stony 
Brook, NY). Short-axis images were acquired through the left ventricle and perpendicular 
to the long axis of the heart using two pulse sequences: (1) a Gradient Echo sequence 
with Flow Compensation (GEFC) to acquire the T2
*-weighted images on which signal 
intensity and contrast-to-noise ratio (CNR) were calculated; and (2) a GEFC cine 
sequence to acquire the movie of cardiac movement, on which cardiac function was 
evaluated. The parameters for the GEFC were: echo time/repetition time (TE/TR) = 
4/120 ms; flip angle (FA) = 30o; field of view (FOV) = 30 x 30 mm; slice thickness = 1 
mm; matrix = 256 x 256 and 8 averages. The parameters for GEFC cine sequence were: 
TE/TR = 4/16 ms; FA = 25o; FOV = 30 x 30 mm; slice thickness = 1 mm; matrix size = 
128 x 128; 8 frames in one cardiac cycle and 8 averages. Both pulse sequences were 
gated using the R-wave of the ECG signal.  
To evaluate the cardiac performance, the left ventricular ejection fraction (LVEF) 





end-systolic volume (LVESV) [LVEF (%) = (LVEDV-LVESV)/LVEDV]. The LVEDV 
and LVESV were determined from the endocardial contours at the end-diastole and end-
systole phase, respectively. The regions of interest (ROI) for calculation were drawn on 
the continuous short-axis MRI slices from the apex to the base covering the entire heart.  
CNR at the MI site was calculated on GEFC images [CNR = (SIMI - SInorm)/SIbkg]. 
SIMI represents the signal intensity at the MI region which was determined as the area 
with wall thinning and further confirmed by the akinetic contractility in the cine images, 
SInorm represents the signal intensity at the normal myocardium, and SIbkg represents the 
background noise. 
2.2.6 Fluorescent Imaging and Histology 
After the MRI session, the heart was removed from the animal and immediately 
fluorescently imaged on the same two-dimensional IVIS 100 Imaging System used for 
the blood sample measurements (n = 4 for MI+MPIO, n = 3 for Sham+MPIO, and n = 2 
for MI-MPIO). Briefly, the heart was put on the stage inside the imaging chamber with 
the infarction site facing up. The parameters used to obtain the primary image were: 
excitation:emission = 500-550:575-650 nm; exposure time = 1 sec; binning = 2; f/stop = 
2; FOV = 5 cm and subject height = 1.5 cm. The parameters for background image were: 
excitation:emission = 460-490:575-650nm; exposure time = 1 sec; binning = 2; f/stop = 2; 
FOV = 5 cm and subject height = 1.5 cm. The corrected image was obtained by 
subtracting the background image from the primary image. One mouse from each group 
was sacrificed for histology after the MRI session at 7 and 14 days post-surgery, 
respectively. Briefly, the animals were perfused first with saline and then with 4% 





7-µm-thick sections. F4/80 staining was performed to stain macrophages and Prussian 
blue staining to confirm the MPIO existence. 
2.2.7 Statistical Analysis  
All data was presented as mean ± standard error of mean (SEM). A two-way 
repeated-measures analysis of variance (ANOVA) was used to compare the difference in 
CNR and LVEF among the three experimental groups. Bonferroni post-hoc test was used 
to compare any two assigned groups. A linear regression was used to determine if a 
correlation existed between the CNR and LVEF for MI+MPIO group. The first-order 
exponential fit was used to estimate the half-life of MPIO washout in the blood pool. The 
GraphPad Prism 5.01 (GraphPad Software Inc., San Diego, CA, USA) was used for all 
statistical analyses. Significance was determined at P < 0.05.  
2.3 RESULTS 
2.3.1 MPIO Blood Kinetics 
Blood kinetics study (Figure 2.1) showed that the fluorescence intensity of blood 
samples reached a maximum within 30 seconds post-MPIO injection. The MPIO was 
quickly washed out from the blood pool with a half-life of less than 1 minute (T1/2 = 0.73 
minute; r2 = 0.94). Therefore, the 7-day interval between MPIO injection and MI was 
sufficient for particles to be cleared from the blood pool, thus minimizing the signal 
attenuation caused by the MPIO otherwise remaining in the peripheral blood. In this 
manner, inflammatory cells mobilizing to the MI site by remote recruitment were 





about MPIO blood kinetics during the myocardial infarction process can be found in 




Figure 2.1 MPIO blood kinetics. Each animal (n = 7) had blood removed at various time 
points up to 8 minutes post-MPIO injection. Fluorescence signal intensity of 50-μl blood 




















Figure 2.2 Longitudinal MR images. MRIs were performed at baseline, 3 days (D3), 7 
days (D7) and 14 days (D14) post-surgery. Temporal signal attenuation was observed at 
the MI site in MI+MPIO group. The short arrows point to the myocardial infarction or 













2.3.2 MPIO-Labeled Inflammatory Cell Infiltration 
Pre-labeled inflammatory cell infiltration into the MI site was monitored and 
examined in T2
*-weighted MRI. As illustrated in Figure 2.2, gradual signal attenuation at 
the MI site was observed in the MI+MPIO group. No detectable signal attenuation was 
observed at the corresponding site in either MI-MPIO or Sham+MPIO group. The MRI 
findings were correlated with histology and fluorescent imaging. In Figure 2.3, Views A 
and B are microscopic pictures of transverse heart slices from a representative MI+MPIO 
heart and Sham+MPIO heart, respectively. Each picture is a montage of approximately 
thirty 10x-magnified microscopic images. A large number of MPIO-labeled cells were 
localized around the MI and adjacent area (Figure 2.3A), while no MPIO-labeled cell was 
observed in the sham heart (Figure 2.3B). Furthermore, the ex vivo fluorescent images for 
the MI+MPIO group showed a strong signal enhancement at the MI site and also the 
adjacent area, indicative of localized MPIO (Figure 2.3E). The Sham+MPIO heart lacked 
fluorescence enhancement (Figure 2.3H). The cross-correlation between MRI, histology 
staining and fluorescent imaging confirmed that the pronounced signal attenuation around 





Figure 2.3 Histology. The images show the transverse heart slices from MI+MPIO and 
Sham+MPIO group, respectively. The MI and sham hearts were excised 7 days post-
surgery. A and B: whole heart slices montaged with approximately 30 microscopic 
images (10x magnification). Arrows in A indicate the iron accumulation in the 
myocardial infarction site. Also observed are iron clusters in the extended area adjacent 
to the MI site. LV: left ventricle; RV: right ventricle. C and D:  correspond to the 
enlargement area boxed with red lines in A. Arrows in C point to some iron-laden cells; 
arrows in D point to the macrophages. F and G: correspond to enlargement area boxed 
with red lines in B. C and F: Prussian blue staining for iron. D and G: F4/80 staining for 
macrophages. E and H: fluorescent images of the representative hearts.  In panel E, also 
observed are enhanced signal intensities beyond the MI site, suggesting extended MPIO 








The histology for the MI+MPIO group further showed the co-localization of 
Prussian blue and F4/80 staining, indicating that an appreciable amount of MPIO were 
incorporated in macrophages (Figures 2.3C and 2.3D). No F4/80 positive or Prussian 
blue stained cell was observed in the Sham+MPIO heart. These results suggested that a 
large number of MPIO-labeled macrophages mobilized, infiltrated, and engrafted into the 
infarcted area of the heart, thereby causing distinguishable signal attenuation in the T2*-








Figure 2.4 CNR and LVEF measurements. A. Temporal signal attenuation at the MI site.
B. Temporal changes of LVEF. (*) P < 0.01, (**) P< 0.001, NS: not significant. C.
Correlating of CNR and LVEF. Plots for different groups are labeled with different
legends. As expected, data points of the sham group form a cluster close to the baseline
points, suggesting no attenuation for both CNR and LVEF. Data points of the MI-MPIO
group show attenuation in LEVF but only minimally in CNR. For the MI+MPIO group,
CNR and LVEF were synchronously attenuated. Further analysis using linear regression
shows a positive linear correlation between CNR and LVEF (r2=0.98). D3, D7 and D14:





CNR at the MI site was calculated to quantify the infiltration of MPIO-labeled 
inflammatory cells into the MI site. The negative CNR values indicated hypointensities 
around the MI site (Figure 2.4A). The more negative the CNR was, the more attenuated 
the signal at the MI site relative to the normal myocardium. The continuous CNR 
attenuation in MI+MPIO group suggested ever-increasing MPIO-labeled inflammatory 
cell infiltration. The CNR decreased dramatically within one week post-MI and changed 
only minimally between 7 days and 14 days post-MI. The CNR at the corresponding sites 
for the two control groups did not show large variation over the experiment course. A 
two-way repeated-measures ANOVA showed a significant difference in CNR values 
between the three treatment groups (P < 0.0001). Bonferroni post-hoc testing further 
showed that the CNR in MI+MPIO group was significantly different from the other two 
groups at all time points after surgery (P < 0.01). No significant difference in CNR values 
at baseline was observed among the three groups. The CNR represents the difference of 
signal intensity between the MI site and normal myocardium. Therefore, these results 
suggest that not only a global infiltration of MPIO-labeled cells occurred at the MI site, 
but also possibly a redistribution of MPIO-labeled cells between the MI site and normal 
myocardium. The concept of redistribution was excluded, however, because relatively 
stable signal intensity was observed in the normal myocardium over the course of each 
experiment. Thus, this CNR data suggests a global MPIO-labeled inflammatory cell 







2.3.3 Temporal Features of Cardiac Performance 
Figure 2.3A illustrates the anatomical morphological changes occurring 7 days 
after the MI. LVEF, a standard clinical measurement, was used to evaluate the resulting 
alterations in post-MI cardiac performance. Ventricular hypertrophy quickly develops 
following a MI in the murine model. LVEF in the MI group decreased dramatically 
within one week post-MI, then somewhat stabilized; the LVEF in the sham group did not 
alter much over the course of the experiment (Figure 2.4B). A two-way repeated-
measures ANOVA showed a significant difference in LVEF between the 3 treatment 
groups (P < 0.0001). As expected, the Bonferroni post-hoc test further showed the LVEF 
in the sham group was significantly different from that of the other two groups at all time 
points after surgery (P < 0.001). No significant difference between the three treatment 
groups was observed at baseline. 
2.3.4 Correlation of Inflammatory Cell Infiltration and Cardiac Function  
A linear regression was used to examine the temporal relationship between 
MPIO-labeled cell infiltration and cardiac function by testing the extent to which CNR at 
the MI site was correlated with LVEF. CNR and LVEF demonstrated similar time-
dependence characteristics for the MI+MPIO group over the 14-day course; both 
measures rapidly attenuated within one week post-MI before they eventually stabilized 
(Figures 4A and 4B). A positive linear correlation (r2 = 0.98, slope = 0.332) was obtained 
between CNR and LVEF (Figure 2.4C). This finding suggests that the post-MI 








This study investigated the temporal characteristics of MI-induced inflammation 
by noninvasively monitoring the infiltration of MPIO-labeled inflammatory cells. In 
contrast to previous studies23, iron oxide particles were injected prior to inducing the MI 
rather than afterward. Using this protocol, the pre-labeled immune cells were 
distinguishable from the activated resident immune cells since only the pre-labeled cells 
mobilizing to the MI site were detected. Surgically inducing the MI after the MPIO were 
cleared from the peripheral blood pool did not allow the local immune cells (activated as 
part of the initial inflammatory response) to phagocytize the circulating MPIO otherwise 
remaining in the blood pool. Furthermore, the entire progress of labeled cell mobilization 
and infiltration could be temporally tracked during the post-MI remodeling process.  
The pre-labeling technique described in this study represents a more effective 
method for studying inflammatory cell behavior compared to injecting in vitro labeled-
cells directly into the infarcted heart. Similarly, Ye and colleagues27 recently 
demonstrated the pre-labeling approach when they tracked recipient macrophages in a rat 
chronic cardiac allograft rejection model. Recent investigations found that the in vitro 
labeling process may affect the functionality of labeled cells and may also cause cell loss 
during and/or after cell injection, leading to a low cell engraftment28. Furthermore, intra-
myocardial injection could further injure the myocardium causing irreversible damage. 
Pre-labeling may potentially promote a variety of cell types, rather than one specific cell 
type, to take up the iron oxide particles. Therefore, a limitation of the current study was 
the unavoidable non-specific cell labeling. T cells, B cells and macrophages are all 





Nevertheless, the iron oxide-enhanced MRI has been demonstrated as an effective 
method for macrophage detection, since the highest MPIO incorporation was observed in 
the culture of macrophages17. 
The half life of iron oxide particles in the blood is dose-dependent and related to a 
progressive saturation of macrophage uptake by various organs3. Hence, the half life of 
MPIO in the blood pool was first measured in this study at the given dose level (14.5 µg 
Fe/g body weight) to determine when the circulating MPIO ceased to provide significant 
contrast enhancement. The short half life (< 1 minute) obtained in this study suggested 
the 7-day interval between MPIO injection and surgery was sufficient for the MPIO 
clearance from blood. Iron oxide particles are predominantly cleared by the RES29 after 
which they accumulate in macrophage-rich organs such as the liver, spleen, bone marrow 
and lymph node6,8. Due to the saturation of macrophage uptake by such organs, a large 
amount of iron oxide particles was expected to remain much longer than the blood half-
life. The 7-day interval should be long enough to ensure an appreciable liver signal 
recovery and to prevent temporal MPIO saturation in such organs. An assumption was 
made that the RES would not readily release MPIO-labeled immune cells until the 
surgically-induced MI triggered the inflammatory response. Nonetheless, quantifying the 
MPIO-labeled cells in the blood sample at baseline and various times after the MI would 
be useful to further consolidate the current findings with those of future studies. Some 
information about the quantification of MPIO-labeled cells in blood can be found in 
appendix A.  
The MRI results demonstrated dramatic changes in both cardiac performance and 





suggest that an early intervention, within one week post-MI, may be fundamental to 
reducing adverse inflammatory responses in the murine model. This study also found that 
the attenuated signal intensity at the MI site was relatively steady after one week post-MI. 
This stabilized signal attenuation may indicate that MPIO-labeled inflammatory cells 
remained in the MI site for an appreciable time period. Thus, future studies should be 
conducted over a longer time span that would potentially capture MPIO washout in the 
post-MI remodeling process. A positive correlation was obtained when correlating CNR 
with LVEF, which implied that the inflammatory cell infiltration was linearly associated 
with reduced cardiac function. However, this finding also warrants further investigation 
since the mechanism and role of inflammation during the MI process was beyond the 
scope of this study.  
Novel methods are warranted to more accurately quantify labeled-cell infiltration 
in MRI, rather than using CNR as the representative index. CNR may exhibit intrinsic 
variation due to fluctuation of the running MR system. CNR values are calculated via the 
mean values of signal intensity of selected ROI. This ROI measurement generally 
represents the mean density of accumulated iron oxide particles rather than detailed 
distribution of labeled cells. Therefore, T2-mapping might be a better way to quantify 
iron oxide-labeled cells. Furthermore, fundamental drawbacks exist for T2
*-weighted 
MRI. The hypointensities may be caused by tissue-interface inhomogeneity, hemorrhage 
and cell necrosis, resulting in misinterpretation of the MRI results. For example, signal 
attenuation was occasionally observed in the left ventricular posterior wall and 
interventricular septum. These artifacts could be caused by cardiac motion, tissue-air 





developing better cell quantification methods, the MPIO dose also warrants further 
optimization. An excessive dose may lead to MPIO saturation around the MI site, while 
an insufficient dose may result in loss of cell tracking. In this initial study, a relatively 
high dose was injected to see if the signal attenuation was feasible for tracking post-MI 
macrophage infiltration. Dose optimization was performed in the subsequent studies. 
2.5 CONCLUSIONS  
This study demonstrated that inflammatory cell mobilization and cardiac 
performance could be noninvasively and temporally monitored in the murine MI model 
using MPIO-enhanced MRI. Continuous signal attenuation around the MI site quantified 
with CNR suggests ever-increasing MPIO-labeled inflammatory cell infiltration. Also, a 
positive linear correlation was obtained between MPIO-labeled cell infiltration and left 
ventricular function during post-MI remodeling. These results support the hypotheses that 
inflammatory cells pre-labeled with an MPIO contrast agent mobilized, infiltrated and 
engrafted to the MI site and could be monitored using T2
*-weighted MRI. This MPIO-
enhanced MRI technique has the potential of quantifying cell infiltration and therefore 
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CHAPTER 3  
MONITORING INFLAMMATORY CELL INFILTRATION 





Myocardial infarction is a leading cause of global deaths and disabilities. 
Inflammation plays a key role in the process of post-MI cardiac remodeling, during 
which inflammatory cells mobilize to the MI site attempting to take away necrotic cells 
and repair the damaged tissue1,2. As superparamagnetic contrast agents, iron oxide 
particles can reduce relaxation time T2 and T2
* and thus produce signal attenuation at the 
target of interest in MRI. Following intravenous administration, iron oxide particles are 
taken up by RES. Inflammatory cells such as monocytes or macrophages which have 
phagocytosed iron oxide particles can thus be detected by MRI. Studies have shown that 
the monocyte or macrophage uptake of iron oxide particles is greatly influenced by the 
particle size, larger particles leading to more efficient cell labeling3,4. Research further 
showed that MPIO provided a higher efficiency for labeling macrophages compared to 
SSPIO and USPIO5. The inflammation process that involves monocyte/macrophage 
traffic can be monitored in many diseases through iron oxide particles-enhanced MRI 
techniques6-8. Iron oxide particles have been used to study infiltration of inflammatory 
cells into the rejected heart9 following transplantation and into the infarcted 
myocardium10 in rodent models.  
It is of fundamental importance to quantify the relative amount of labeled cells 





information regarding cell population, disease progression or treatment effect. Many 
studies have focused on in vitro quantification of iron oxide particle-labeled cells11,12. 
These studies are useful for determining the MR property of a particular type of iron 
oxide particles such as their T1 and T2 relaxivites, and to provide insight for further in 
vivo study. However, there are essential differences between the in vitro and in vivo 
environment. The relaxation times T1 and T2 are dependent not only on the type of iron 
oxide particles and iron concentration, but on the particle distribution as well as the 
microenvironment surrounding the iron oxide particle, i.e., the cell compartmentalization, 
water content and ionic environment. The substantial differences between the in vivo and 
in vitro environments make it imperative to calibrate an in vivo relationship projecting the 
signal intensity or relaxivity to the number of labeled cells, before taking further steps to 
quantify disease progression or to evaluate treatment effect.  
The previous study demonstrated that infiltration of inflammatory cells can be 
noninvasively and longitudinally monitored during the MI using MPIO at a dose level of 
14.5 µg Fe/g body weight13. The main purpose of this dose-dependent study is to 
optimize the MPIO dose as well as the temporal window for inflammatory cell tracking. 
In addition, this study investigated the connection between the MR signal intensity at the 
MI site and the infiltration rate of labeled cells. In order to assess the cell infiltration, it is 
fundamentally important to correlate the MR signal intensity with the features of cell 
infiltration, such as the cell infiltration rate or even the density of labeled cells at the 
infarction site. The information acquired from this study can potentially be translated to 
other cell labeling studies, e.g. stem cell labeling and tracking, and provide useful clues 






3.2.1 Animal Preparation  
Adult male C57Bl/6 mice (n = 57; 24.8±2.7 g; 6–12 weeks old) were used in 
compliance with the Institutional Animal Care and Use Committee at the Medical 
College of Georgia, Augusta, GA, USA. The procedures have been described in the 
previous chapter. Briefly, the animals were anesthetized with a mixture of medical air, 
oxygen, and isoflurane, and then put in a prone position on the animal cradle. The 
isoflurane was maintained at ~1.5% throughout all MRI sessions. During this dose-
dependent study, the animals were maintained at a constant animal respiration rate of 
65±7 breaths per minute and a heart rate of 441±52 beats per minute. 
Animals were divided into 5 dose groups: 14.5, 9.1, 3.6, 1.1 µg Fe/g body weight 
and a control group without any MPIO injection. The MPIO were injected into the animal 
blood stream intravenously. At 7 days post-injection, the animals underwent surgery to 
induce MI. MR images were acquired at 1 day before MI surgery (baseline), 3 days (D3), 
7 days (D7), 14 days (D14) and 21 days (D21) post-MI. The experiment time course is 
shown in Figure 3.1. 
 






3.2.2 Contrast Agent 
The iron oxide contrast agent used in this study was Bangs particles (a type of 
MPIO, Catalog code: ME03F; Bangs Laboratories, Inc., Fishers, IN, USA). Bangs 
particles have been described in chapter 2. Briefly, these particles have a mean diameter 
of 1.63 µm, with a magnetite core (42.5% weight) coated with a polymer (P(S/V-
COOH)Mag/Encapsulated). These particles are also tagged with a fluorescent dye 
(Suncoast Yellow fluorescence, excitation:emission = 540:600 nm). For animals 
receiving the highest dose, the undiluted MPIO solution (original concentration of 
2.793x109 particles per mL) was injected via tail vein at a dose of 14.5 µg Fe/g body 
weight (i.e., 1.31x107 particles/g body weight). For the lower dose levels, the MPIO 
solution was diluted in proportion using saline solution while maintaining a relatively 
consistent total injection volume. For example, when the dose was 3.6 µg Fe/g body 
weight, the concentration was first diluted into 2.793 x 109 x (3.6/14.5) = 6.934x108 
particles/g body weight and then a volume corresponding to the animal’s weight was 
injected.   
3.2.3 MI and MRI 
The MI or sham surgeries were performed as previously described in chapter 2. 
Briefly, mice were anesthetized with an intraperitoneal injection of ketamine/xylazine. 
The animals had their left anterior descending coronary artery permanently ligated to 
induce an acute infarction in the left ventricular myocardium. The animals were then 
allowed to rest for 3 days before MRI.  
As described in chapter 2, T2
*-weighted MR images were acquired on a horizontal 





a micro-imaging gradient insert (950 mT/m).  A 35mm inner diameter volume coil was 
used to transmit and receive at 1H frequency (300 MHz). The ECG and respiratory 
signals were monitored and used for gating by a physiological monitoring system (SA 
Instruments, INC., Stony Brook, NY). Short-axis images were acquired through the left 
ventricle and perpendicular to the long axis of the heart using two pulse sequences: (1) a 
GEFC sequence to acquire the T2
*-weighted images on which signal intensity and CNR 
were calculated; and (2) a GEFC cine sequence to acquire the movie of cardiac 
movement, on which cardiac function was evaluated. The parameters for the GEFC were: 
TE/TR = 4/120 ms; FA = 30o; FOV = 30 x 30 mm; slice thickness = 1 mm; matrix = 256 
x 256 and 8 averages. The parameters for GEFC cine sequence were: TE/TR = 4/16 ms; 
FA = 25o; FOV = 30 x 30 mm; slice thickness = 1 mm; matrix size = 128 x 128; 8 frames 
in one cardiac cycle and 8 averages. Both pulse sequences were triggered by the R-wave 











*-weighted longitudinal short-axis cardiac MR images from the macrophage 
study. The signal intensity at the infarction site (indicated by dark arrows) was attenuated 
temporally for both groups with iron injection. More signal attenuation was observed at 











Figure 3.3 Identification of the MI zone. The thickness of the left ventricular wall (A) 
and normalized MR signal intensity (B) at each radiant angle was plotted. The center of 
the MI zone was set to 180° as demonstrated in the inserted image on the lower left. The 
signal intensity at the infarction zone was obtained after the MI zone was identified. 








3.2.4 Image Processing and Data Analysis 
MR images were processed using an in-house program developed in MATLAB 
(MathWorks, Inc., Natick, MA). A description of this program can be found in appendix 
C. Normalized signal intensity (nSI) method was used to illustrate the signal intensity 
attenuation at the MI site. In the nSI analysis, the signal intensity was normalized to the 
maximum signal intensity from the ventricular blood. During the image analysis, the left 
ventricular wall was outlined manually and then its thickness was curve fitted. Examples 
of cardiac images are shown in Figure 3.2. The infarction site (indicated by arrows) with 
attenuation in both wall thickness and MR signal intensity can be observed at D7 and 
D14. By curve fitting the thickness of the left ventricular wall, the MI zone can be 
automatically identified, as it corresponds to the region with attenuated thickness (Figure 
3.3Top). The signal intensity at the infarction site was acquired after the MI zone was 
identified. (Figure 3.3Bottom). This image analysis procedure by and large reduces the 
bias otherwise produced when the image analyst subjectively localizes and manually 







Figure 3.4 Comparison and correlation of CNR and nSI analysis. The data was expressed 
with mean ± SD. A. CNR and nSI are plotted side by side with scale approximately 
matched with each other. The coefficient of variance is smaller for nSI at all time points 
post-MI. B. Pearson correlation analysis demonstrated CNR was well correlated with nSI 




A comparison between the nSI and CNR method showed that the nSI method was 
a better way for quantitative analysis in the current study. In the traditional CNR method, 
CNR at the MI site was calculated by CNR = (SIMI − SInorm)/SIbkg. SIMI represents the 
signal intensity at the infarction region, which was determined as the area with 
ventricular wall thinning; SInorm represents the signal intensity at the normal myocardium; 
and SIbkg represents the background noise. Figure 3.4 demonstrates the comparison 
between the nSI and CNR. A good match between CNR and nSI can be seen in Figure 
3.4A, with both showing a similar temporal trend of signal attenuation with time. A 
significant correlation between nSI and CNR is shown in Figure 3.4B (r2=0.92, P < 0.01). 
To compare the coefficient of variation (CV) at each time point, the CNR was converted 
to nSI first, according to the linear regression formular [nSI = 0.009523 x CNR + 0.1704]. 
The standard deviation (SD) of CNR was also scaled by a multiplication factor of 





smaller than the scaled CV of CNR [Scaled CV = Scaled SD / Scaled mean]. Therefore, 
nSI analysis was determined to be a more accurate method and thus was used to quantify 
the signal attenuation at the MI site.   
 
 
Table 3.1 Comparison between CNR and nSI 
Time 
CNR nSI 






Mean SD CV 
Baseline 0.12 4.47 37.25 0.17 0.04 0.25 0.17 0.03 0.16
D3 1.21 4.51 3.73 0.18 0.04 0.24 0.18 0.04 0.23
D7 -2.98 4.03 1.35 0.14 0.04 0.27 0.13 0.01 0.11
D14 -5.46 3.6 0.66 0.12 0.03 0.29 0.10 0.02 0.14
D21 -7.51 4.84 0.64 0.10 0.05 0.47 0.11 0.03 0.24




To connect the serial MR signal intensity at the MI site with the cell infiltration 
rate, the rate of attenuation (ROA) of nSI was calculated [ROA = ABS(nSIcurrent– 
nSIprevious)/nSIprevious/(Datecurrent–Dateprevious)]. ABS is denoted as the mathematical 
operation of calculating the absolute value. For example, the ROA from 3 to 7 days post-
MI is calculated as ROA3-7 = ABS(nSI7– nSI3)/nSI3/(7 day–3 day)]. The unit for ROA is 
percentage per day (% per day). The ROA is used as an indirect index of labeled cell 
infiltration rate.    
To evaluate the cardiac performance, the LVEF was calculated using the LVEDV 
and LVESV [LVEF (%) = (LVEDV-LVESV)/LVEDV]. The LVEDV and LVESV were 





respectively. The ROIs for calculation were drawn on the continuous short-axis MRI 
slices from the apex to the base covering the entire heart. 
3.2.5 Statistical Analysis 
All data were presented as mean ± SEM in the result section. A two-way 
repeated-measures ANOVA was used to compare the difference in LVEF among the five 
experimental groups. A Pearson correlation analysis was used to determine if a linear 
correlation existed between the nSI and the injected MPIO dose at each time point. 
Student t-test was used to examine the temporal and dose-dependent characteristics of 
nSI by comparing any dose groups with the control group at each time point. The 
GraphPad Prism 5.01 (GraphPad Software Inc., San Diego, CA, USA) was used for all 




















Figure 3.5 Temporal and dose-dependent analysis. A. A dose-dependent plot of 
normalized signal intensity (nSI) at the infarction site with time. Higher dose level 
produced more signal intensity attenuation at 7 and 14 days post-MI. B. Linear regression 






Figure 3.6 Variance of the ROA of the nSI due to differential doses. The ROA of nSI is 
an indicator of the infiltration rate of the labeled cells to the MI site. D3, D7, D14 and 








The cell infiltration during MI was successfully monitored using MPIO cell 
labeling and T2
*-weighted MRI technique. The signal intensity at the MI site was 
continuously attenuated following infarction until 14 days post-MI, at all dose levels. 
This dose-dependent study demonstrated that a higher dose produces more attenuation at 
the infarction site (Figure 3.2). The quantitative results are shown in Figure 3.5. For each 
dose group, continuous signal attenuation was observed until 14 days post-MI. The signal 
intensity stabilized after 14 days, which resulted in relatively small signal differences at 
21 days post-MI at different dose levels. Most interestingly, an inverse linear relationship 
between the nSI and MPIO dose was found at both 7 days (r2=0.92) and 14 days (r2=0.98) 
post-MI using linear regression. No such strong relationship was evidenced at other time 
points (r2=0.08, 0.55, 0.75 for baseline, 3 days and 21 days post-MI). The inverse linear 
relationship potentially suggests that higher MPIO doses can effectively lead to more 
labeled cell accumulation at the MI site. The wide range of signal intensity produced by 
different doses indicates that MPIO is utilized more effectively at 7 days and 14 days 
post-MI. The variance of the ROA of the nSI due to differential doses is demonstrated in 
Figure 3.6. It is deemed that the variance of the ROA at one given temporal interval was 
primarily caused by the difference in the injected MPIO dose, but not by the surgical 
variation. The ROA with minimal variation among time points occurred from 7 to 14 
days post-MI, indicating that the error caused by the difference in the injected dose can 
potentially be minimized when using the MR signal intensity to interpret the cell 





optimal temporal window for MR imaging of the labeled cells at the MI site, which is 
determined to be from 7 days to 14 days post-MI.  
 
 
Table 3.2 P values of student t-test compared with control 
Time 1.1 µg/g 3.6 µg/g 9.1 µg/g 14.5 µg/g 
Baseline NA 0.1045 0.0810 0.4121 
3 days 0.3449 0.2820 0.4848 0.0576 
7 days 0.2209 0.2222 0.0276 0.0004 
14 days 0.1915 0.1633 0.0081 0.0002 




Student t-test was used to compare the signal difference between any dose group 
and the control group. The results are shown in Table 3.2. Significant differences in 
signal intensity were found between the control group and the 9.1 µg/g dose group or the 
14.5 µg/g dose group, at both 7 days (P = 0.03, 0.0004 for the 9.1 µg/g, 14.5 µg/g dose, 
respectively) and 14 days post-MI (P = 0.008, 0.0002 for the 9.1 µg/g, 14.5 µg/g dose, 
respectively). The signal intensity of lower dose groups was not significantly different 
from that of the control group at either 7 or 14 days post-MI (P > 0.05 for the 1.1 µg/g or 
3.6 µg/g dose group). At baseline or 3 days post-MI, there was no significant difference 
in signal intensity between the control group and any dose group (P > 0.05). The 
significant difference in signal intensity at 7 days and 14 days post-MI indicates that a 
dose of no less than 9.1 µg/g should be administered in order to quantify the labeled cells 





posterior ventricular wall and interventricular septum, which also produced signal 
attenuation and could potentially be misinterpreted as signal attenuation caused by iron 
oxide particles. A dose less than 9.1 µg/g may not be able to produce sufficient signal 
attenuation. Therefore, the optimal dose for tracking labeled cells following MI should be 
no less than 9.1 µg/g, but no more than 14.5 µg/g.     
The left ventricular ejection fraction (Table 3.3) was compared using a two-way 
ANOVA test. The results showed no significant difference in the LVEF by surgical 
treatment among all animal groups (P = 0.45), which indicates that the signal attenuation 
at the MI site was not caused by surgical variation. Since the variation in MPIO dose did 
not affect the cardiac function, the animals from different dose groups were grouped 
together to examine the alteration of cardiac function parameters following MI. Those 
results are shown in Table 3.4. Following MI, both the LVEDV and LVESV increased 
with time, but the LVEF decreased. The most dramatic changes in cardiac remodeling 
occurred within 14 days post-MI. The situation stabilized after 14 days. This cardiac 
function turnover matched the findings on signal intensity, which also reached a 









Table 3.3 Left ventricular ejection fraction (%) 
Time Control 1.1 µg/g 3.6 µg/g 9.1 µg/g 14.5 µg/g 
Baseline 69.34±3.29 NA 72.26±2.03 73.34±1.38 70.68±1.79 
D3 51.26±4.33 54.99±1.33 48.91±2.10 52.90±3.14 49.68±3.50 
D7 38.09±2.75 47.40±2.70 38.88±4.19 46.63±4.20 41.28±3.39 
D14 43.42±4.07 50.86±1.50 40.19±4.40 48.11±4.91 41.16±4.10 
Note: the numbers of samples for each measurement varies from 6 to 13. Data for 




Table 3.4 Cardiac physiology data 
Time EDV (mL) ESV (mL) SV (mL) LVEF (%) LVWM (mg) 
Baseline 49.43±1.68 13.87±0.95 35.55±1.17 72.12±1.32 107.84±2.84 
D3 65.41±2.36 32.45±1.96 32.96±1.40 50.68±1.89 118.91±2.59 
D7 84.00±4.80 50.68±5.05 33.32±1.11 41.77±2.84 127.44±3.83 
D14 92.61±6.41 56.97±7.40 35.64±1.45 42.01±3.61 168.44±4.71 
D21 97.69±7.94 58.83±8.38 38.86±1.31 43.58±3.29 133.25±3.25 
D28 101.11±9.00 61.10±8.66 40.01±1.34 42.96±2.86 143.79±5.09 
Note: the data was from 16 animals that received varied doses. EDV, ESV, SV, LVEF 
and LVWM denote left ventricular end-diastolic volume, end-systolic volume, stroke 








This study demonstrated an indirect method for quantification of labeled cell 
infiltration in cardiac MRI by using signal intensity at regions of interest normalized to 
the signal intensity from the ventricular blood. The image analysis showed that the 
normalized signal intensity has a smaller systemic statistical variation than CNR dose. 
The systemic deviation stems mainly from the variation of scan parameters such as the 
acquisition gain or even attenuation values, which are subject to the user’s setup during 
each imaging session. To achieve optimal image quality, it is necessary to increase the 
acquisition gain as the iron oxide particles accumulation in injured tissues inside an 
imaging plane caused pronounced signal attenuation. The changes of acquisition gain as 
well as the fluctuation of spectrometer over time could influence the CNR, in particular, 
by causing dramatic variations in background noise. When using signal intensity as an 
analysis index, it is intuitive and common to normalize the signal intensity at a region of 
interest to that from a phantom which may contain water or oil. In cardiac imaging, the 
ventricular blood provides a natural and convenient phantom for signal correction, as 
long as the blood is not contaminated with contrast media. In this study, the MPIO were 
rapidly washed out of the blood, with a half life of less than 1 minute. Consequently, it 
was determined that the ventricular blood should not be contaminated by MPIO at the 
time of MRI. 
Iron oxide particles provide image contrast by causing signal loss at the MI site. 
However, it is difficult to differentiate the signal attenuation caused by labeled cells from 
that caused by hemorrhage. Attenuation due to hemorrhage also can affect signal 





agents. Although some imaging sequences or post-processing methods have been tried 
via recognition of the signal pattern caused by iron oxide particles14-21, execution of these 
methods usually requires a  great deal of effort for preparation and optimization. In 
addition, some methods become impractical when many labeled cells cluster together and 
a great number of particles accumulate even in one single image voxel, which is usually 
the case when iron oxide particles are administered intravenously. While using relaxation 
time T2 or T2
* is a better choice for quantification than using signal intensity, several 
limitations exist in cardiac imaging. First, the image registration in multi-echo sequences 
is sensitive to cardiac motion. Second, T2
* can be shortened to such a large extent that T2
* 
measurement may have an intolerable error. In addition, detecting a short T2
* requires a 
short starting echo time and thus a high power. Future investigation such as using MRS is 
encouraged to generate better methodology for quantification of labeled cells.     
The activity of labeled cells infiltration intensified within 14 days post-MI and 
caused significant signal attenuation at the MI site from 7 days to 14 days post-MI. A 
wide range of signal intensity produced by varied doses during this optimal temporal 
imaging window suggests that further experiments in quantification of labeled cells at the 
MI site should be performed within this time interval. In future research, MRI 
experiments performed on more time points between 3 and 14 days post-MI may refine 
the optimal temporal window for the interpretation of the cell infiltration rate. It will be 
necessary to find a better way to correlate the signal intensity or relaxivity with the cell 
infiltration rate, or even with the number of labeled cells at the MI site. The ROA of the 
nSI at the MI site is an indirect index for the infiltration rate of the labeled cells. While 





For instance, the dose difference may lead to variation in in vivo cell labeling efficiency. 
Because no significant difference in the LVEF was observed among all dose groups, the 
variance of the ROA due to variation in surgical procedures was minimized. Further 
experiments can be performed to test whether the technique developed from this study is 
sensitive enough to differentiate any drug effect on labeled cell mobilization.  
3.5 CONCLUSIONS  
This study provided a convenient method to quantify signal intensity attenuation 
caused by labeled cells in cardiac MRI. The signal intensity at the infarction site 
normalized to that from the ventricular blood was well correlated with the CNR but had 
less variation than the CNR did. The study suggests that the dose to quantify any effect 
on cell infiltration by potential treatment strategies should be no less than 9.1 µg/g but no 
greater than 14.5 µg/g. A dose-dependent phenomenon of labeled cell infiltration into the 
MI site was evidenced, each dose leading to a different number of labeled cells at the MI 
site reflected from the MR signal intensity attenuation. Furthermore, a linear dependence 
of MR signal intensity on injected MPIO dose was observed at 7 and 14 days post-MI. 
This linear signal-dose relationship further suggests an optimal temporal imaging window, 
which is between 7 and 14 days post-MI. During this time interval, the variance of ROA 
of the nSI due to the dose difference was also minimized. Future investigation is 
necessary to delineate a direct relationship between the signal intensity and the cell 
infiltration rate, or even the relative number of labeled cells at the infarction site. The 
current cell labeling and MR imaging techniques can potentially be applied to track and 
quantify cell infiltration in cell therapy and drug treatment or to monitor disease 
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CHAPTER 4  





A major complication of MI is heart failure1, since the scar tissue healing over the 
necrosed myocardium contains no contractile or pacemaker myocytes2. Stem cell-based 
therapies have been explored to potentially regenerate healthy tissue at MI sites, given 
that the heart lacks the necessary cardiomyocyte progenitors to do so by itself3. However, 
the roles of stem cells in the myocardial repair and remodeling processes are yet to 
know4,5. 
Cells such as ESC6, human ESC-derived cardiomyocytes7, skeletal myocytes8 and 
bone marrow-derived stem cells9,10 have been previously transplanted into infarcted 
myocardium. However, complications have occurred when applying these cells to 
myocardial repair, including adverse immunological response and/or teratoma 
formation11, highly complex harvest process12 and failure to functionally integrate with 
the host tissue13. Compared with other cell types, MSC demonstrate advantages in cardiac 
cell therapy since they exhibit a multi-lineage plasticity, a reduced immune response, and 
an easy harvest process14,15. Research by Quevedo et al16 showed that MSC were capable 
of restoring cardiac function with an increase of ejection fraction from 35.0±1.7% to 
41.3±2.7 over 12 weeks in swine receiving transendocardial injection of 200 million 
MSC.  
Previous studies attempted to improve cardiac structure and function by directly 





usually led to severe cell loss12. Studies also showed that intracoronary and intravenous 
injections were no more successful than the intramyocardial route at rendering 
satisfactory graft efficiency17-19. Furthermore, transfer of iron oxide particles form 
originally labeled cells to macrophages can lead to false interpretation of MRI data20,21, 
which imposes additional disadvantage for intramyocardial delivery. Intra-bone marrow 
transplantation is an alternative delivery method, which has exhibited improved 
engraftment22. The bone marrow milieu provides a native environment for transplanted 
cell engraftment and proliferation.  
Therefore, the purpose of this study was to investigate MSC’ infiltration traffic 
from the bone marrow to MI sites by an intra-bone marrow cell delivery method. MSC 
were labeled with enhanced green fluorescent protein (GFP) and MPIO, which are also 
tagged with a Suncoast Yellow fluorescent dye. MPIO labeling enabled the noninvasive 
cell tracking with MRI. Fluorescence from both GFP and MPIO was used to confirm the 
MRI findings by histological fluorescent imaging. This study intended to demonstrate 
that combining intra-bone marrow cell delivery, dual-cell labeling and MRI cell tracking 
is a promising methodology for studying stem cells mobilization in animal MI models.  
4.2 METHODS 
4.2.1 Overall Experimental Protocol 
All animal procedures were performed in compliance with the Institutional 
Animal Care and Use Committee at the Medical College of Georgia, Augusta, GA. Adult 
male C57Bl/6 mice (6-12 weeks old, 23.8±3.0 g) underwent irradiation, unlabeled 





of the labeled MSC (two days after irradiation). At 14 days after labeled MSC 
transplantation, one animal group underwent MI surgery as an experimental group 
(Experimental group, n=7); another group underwent sham-operated surgery 
(thoracotomy without any heart injury) as a sham control group (Sham control, n=7). A 
third group receiving neither irradiation nor cell transplantation underwent MI surgery 
(MI control, n=6) as MI control. MRIs were performed on all mice at baseline, 3 days 
(D3), 7 days (D7), and 14 days (D14) post-MI or sham surgery. Figure 4.1 illustrates the 
overall experimental time course. 
 
 




4.2.2 MSC Isolation and Culture 
Bone marrow was harvested from 18-month-old C57Bl/6 mice by flushing the 
femora and tibiae with complete isolation medium (CIM) consisting of RPMI-1640 with 
9% heat-inactivated fetal bovine serum, 9% horse serum, 100 U/mL penicillin, 100 
µg/mL streptomycin, and 12 µmol/L L-glutamine23. The bone marrow was then dispersed 
into single-cell suspension and plated in flasks. To minimize MSC contamination with 
hematopoietic progenitor cells, the bone marrow cell suspension was allowed to adhere to 
the flasks for 3 hours at 37°C in a 5% CO2 atmosphere





the flask containing adherent cells gently washed with phosphate-buffered saline (PBS), 
and the cells cultured in CIM until they reached 80% confluence. Cells were then lifted 
by trypsin and subjected to negative immuno-selection by using magnetic beads to 
remove any hematopoietic lineage cells25. The magnetic beads had been conjugated with 
CD11b, CD11c, CD45R/220B, and PDCA-1 monoclonal antibody. The hematopoietic 
lineage cells removed in this process included granulocytes, macrophages, myeloid-
derived dendritic cells, natural killer cells, B-1 cells, B lymphocytes, T lymphocytes, 
classical dendritic cells, plasmacytoid dendritic cells, and macrophage progenitors. 
Lastly, all cells negative for these antigens were subjected to a positive immuno-selection 
using stem cell antigen-1 (Sca-1) monoclonal antibody conjugated magnetic beads.  
4.2.3 MSC Labeling and Delivery 
First, MSC were fluorescently labeled with GFP via infecting the cells with 
retroviral vectors expressing GFP (∆U3-GFP)26. The GFP allowed cells to be visualized 
in fluorescent imaging. Next, the MSC were magnetically labeled with 1.63 μm MPIO 
(Bangs Laboratories, Fishers, IN). MPIO have a polymer-coated magnetite core (42.5% 
weight) and are tagged with a Suncoast Yellow fluorescent dye. The magnetic core and 
Suncoast Yellow fluorescence allowed MPIO to be visualized via MR and fluorescent 
imaging, respectively. For labeling, MPIO were opsonized in 50% fetal bovine serum for 
1 hour at 37oC, washed in PBS and resuspended in 1 mL expansion media with a 
concentration of 1x108 MPIO per mL. Then MSC were incubated in 10 mL of media with 
a concentration of 106 MPIO per mL for 48 hours.  
Labeling outcomes were evaluated using a Zeiss Axiovert 10 microscope (Carl 





Sterling Heights, MI). The dual-labeled MSC were identified by the co-localization of 
GFP and Suncoast Yellow fluorescence. Labeling efficiency was measured by randomly 
selecting labeled-cell cultures. The ratio of the number of dual-labeled cells to the total 
cell number was calculated within a single fluorescent image (20x magnification). MSC 
were further examined under an electron microscope to confirm MPIO were inside the 
cells. These dual-labeled cells maintained their capability of differentiation during a 10-
day observation. More information about MSC differentiation in culture and bone 
marrow can be found in appendix B.        
For the Experimental and Sham control groups, animals underwent irradiation 
with 137Cs using a Gammacell 40 irradiator (Best Theratronics, Ottawa, ON, Canada). A 
dose of 8.0 Gy was used to ablate the bone marrow. The animals received a rescuing 
donation of unlabeled ~0.5-2 x106 bone marrow cells via retro-orbital plexus injection 
within 24 hours after irradiation. Two days after the irradiation, each animal was properly 
anesthetized with a mixture of medical air, oxygen (1:1), and ~2.0% isoflurane (Abbott 
Laboratories, Abbott Park, IL), and a hole was drilled into the proximal articular surface 
with a 26-gauge needle. Then ~30-50 µL of bone marrow was aspirated from the bone 
marrow cavity, and ~6.6x105 GFP and MPIO dual-labeled MSC (1.3 million cells per mL 
in PBS) were transplanted into the tibial medullary space. The mice were allowed to 
recover in a post-operative recovery chamber under careful supervision before being 






4.2.4 MI and MRI 
The MI and sham surgeries were performed two weeks after MSC transplantation 
using previously described procedures27. Briefly, mice were anesthetized with an 
intraperitoneal injection of ketamine/xylazine at a dose of 2 µL/g body weight. The 
sham-group mice had their chests immediately sutured after performing the thoracotomy 
without injuring the heart. The MI-group mice had their left anterior descending coronary 
artery permanently ligated to produce an acute infarction in the left ventricular 
myocardium. The mice were then allowed to recover for 3 days before next MRI.  
MRI procedures were conducted using a previously described protocol27. Briefly, 
each mouse was anesthetized with a mixture of medical air, oxygen (1:1), and 1.5-2.0% 
isoflurane, maintaining a respiration rate of 61±6 breaths per minute and a heart rate of 
434±58 beating per minute for all MRI sessions. MRI was performed on a horizontal 7-T 
MRI spectrometer (Bruker Instruments, Billerica, MA). Short-axis cardiac images were 
acquired through the left ventricle perpendicular to the long axis of the heart using two 
pulse sequences: (1) an ECG-gated GEFC sequence that acquired single T2
*-weighted 
images, and (2) an ECG-gated GEFC cine sequence that acquired movies of cardiac 
movement during the cardiac cycle. The GEFC sequence was sensitive enough to detect 
the signal attenuation generated by MPIO, while the LVEF was calculated from the 
GEFC cine sequences.  
LVEF was calculated using the LVEDV and LVESV determined from the 
endocardial contours in the end-diastolic and end-systolic phases, respectively [LVEF(%) 





measurements in the GEFC T2
*-weighted images [CNR = (SIMI - SInorm)/SIbkg]. The SIMI 
represented the signal intensity at the MI region located where the left ventricular wall 
thinned; the MI region was confirmed by the akinetic contractility area seen in the cine 
images. The SInorm represented the signal intensity in the normal (non-infarcted) 
myocardium and the SIbkg represented the background noise.  
4.2.5 Histology 
After completing the final MRI session and while still anesthetized, each animal 
was sacrificed by perfusing the body with 4% paraformaldehyde (PFA) injected into the 
inferior vena cava. Once the blood was flushed out, the heart was removed from the body. 
After two days in PFA, the heart was immersed in 30% sucrose and then sectioned into 
10 µm-thick transverse slices along the longitudinal axis. These tissue slices were then 
immuno-labeled with antibodies against a fibroblast marker ER-TR7, 
macrophage/monocyte marker F4/80 and CD11. All slices were examined under a 
confocal microscopy (Zeiss LSM 510 laser scanning microscope; Carl Zeiss, Jena, 
Germany) for fluorescent imaging. 
4.2.6 Statistical Analysis  
All data were presented as mean ± SEM. A two-way repeated-measures ANOVA 
analysis was used to compare differences in CNR and LVEF values between different 
groups followed by Bonferroni post-hoc tests. The GraphPad Prism 5.01 (GraphPad 
Software Inc., San Diego, CA) was used for all statistical analyses with a significance 








Figure 4.2 Dual-labeled MSC with GFP and MPIO. A. A merged fluorescent image of 
dual-labeled MSC. The GFP expression is in green and MPIO are indicated by red spots. 
B. Image from an electron microscope showing MPIO engulfment inside a cell. The 






4.3.1 MSC Labeling  
Figure 4.2 demonstrates the dual-labeled MSC. Figure 4.2A shows the co-
localization of GFP and MPIO in these cells with the GFP expression shown in green and 
MPIO represented by red spots. Figure 4.2B is an image from an electron microscopy 
confirming that MPIO were incorporated into the MSC. Based on ten random 









4.3.2 MRI Cell Tracking 
Figure 4.3 shows an example of longitudinal T2
*-weighted MR images acquired to 
monitor labeled MSC infiltration into the MI sites. Gradual signal attenuation was 
observed in infarction sites over time for the Experimental group. No remarkable 
attenuation was observed at the corresponding sites for the Sham control mouse. Low 
signal intensity localized in the posterior left ventricular wall was presumably artifacts 




*-weighted short-axis cardiac MR images. Gradual signal attenuation was 
observed at MI sites for the Experimental group, suggesting labeled cells accumulation. 
No remarkable signal attenuation was observed for sham group. Arrows indicate MI or 







Figure 4.4 CNR and LVEF. A. Continuous CNR attenuation for the Experimental group 
suggests labeled MSC infiltration into MI sites. B. Decrease in LVEF for both the 
experimental and MI control group evidences MI-caused cardiac dysfunction. NS: not 




Temporal infiltration of MPIO-labeled MSC at the MI site was quantified using 
CNR (Figure 4.4A). The negative CNR values seen for the Experimental group 
represents signal attenuation around the MI site indicative of MPIO-labeled cell 
infiltration. The continuous CNR attenuation over time denotes an increased MPIO-
labeled cell infiltration into the infarction site, which was not observed in either the Sham 
or MI control group. Two-way repeated measures ANOVA test showed significance 
difference in CNR among all groups (P < 0.0001). As expected, no significant difference 
in CNR were found between any two groups at baseline (P > 0.05). Significant 
differences in CNR were found between the experimental group and Sham control group 
at 3 days (P < 0.01), 7 days (P < 0.001) and 14 days (P < 0.001) post-MI, and between the 
experimental group and MI control group at 7 days (P < 0.05) and 14 days (P < 0.001). 
The post-MI CNR attenuation for the MI control group was presumably caused by 





attenuation for the Experimental group indicates that the MPIO-labeled cells mobilized 
into the MI site from bone marrow and was successfully monitored with the T2
*-weighted 
MRI technique.  
LVEF was evaluated as a representation of cardiac performance (Figure 4.4B). As 
expected, LVEF decreased following the MI surgery and gradually stabilized after 7 days 
for both the Experimental and MI control group. Two-way repeated measures ANOVA 
test showed significance difference in LVEF among all groups (P < 0.0001). While no 
significant difference in LVEF were found between any two groups at baseline (P > 0.05), 
significant differences in the LVEF were found between the Experimental group and 
Sham control group at 3 days (P < 0.01), 7 days (P < 0.001) and 14 days (P < 0.001) post-
MI. No significant difference was found between the experimental group and MI control 
group at each time point (P > 0.05).  
4.3.3 Histological Fluorescent Imaging 
Fluorescent confocal imaging provided a 3-dimentional view of the histology 
slices. Therefore this method is well-suited to examine the co-localization of dual labels. 
Figure 4.5A illustrated the dual-labeled MSC at the MI site, with GFP labeling identified 
by the green color and MPIO labeling by the red spots. This finding confirmed that dual-
labeled MSC mobilized from the bone marrow into the MI site, thus validating MRI 
findings. Figure 4.5B shows that a subset of GFP labeled MSC were also positive for ER-
TR7 (i.e., the fibroblast biomarker). This merged image shows ER-TR7 expression in red 
and GFP in green. The overlap between ER-TR7 and GFP turned the color yellow, 





site. These histological findings confirmed that the dual-labeled MSC maintained their 
capability of proliferating, migrating and differentiating following intra-bone marrow 
transplantation. Additional immunohistological staining with F4/80 and CD11b 




Figure 4.5 Three-dimensional histological fluorescent images. A. Dual-labeled MSC 
contained both GFP (green color) and MPIO particles (red spots). B. GFP+ MSC and/or 
derivatives (green color) were positive to ER-TR7 antibody, a fibroblast marker (red 














This study demonstrated how combining the in vivo MRI and ex vivo fluorescent 
imaging techniques assessed the temporal characteristics of MSC homing to MI sites 
following their intra-bone marrow transplantation. Dual labeling of MSC with GFP and 
MPIO allowed noninvasively and temporally tracking MSC infiltration into the MI site, 
as well as histological confirmation of the MRI findings. MRI data illustrated the post-MI 
attenuation of CNR over time, indicating that mediation of MSC in myocardial 
remodeling lasted at least two weeks. MRI findings were confirmed by histological 
fluorescent imaging, in which a considerable number of dual-labeled cells were observed 
around the MI site. 
The intra-bone marrow transplantation technique provided a unique cell delivery 
method for studying bone marrow-originated stem cells in post-MI animal models, since 
the bone marrow provides a native environment for implanted cells to survive and 
proliferate. This study showed that dual-labeled MSC maintained their capability of 
migrating and differentiating following intra-bone marrow transplantation. Once 
irradiation prepared the bone marrow for MSC engraftment, the two-week span between 
the transplantation and sham/MI surgeries proved to be an adequate amount of time for 
this cell engraftment to occur. More information about MSC engraftment in the bone 
marrow can be found in appendix B. 
In this research, the MI was determined by the thinning of the infarction area and 
further confirmed by its contraction inability. In the future study, the infarction area can 





outlined by using gadolinium-based contrast agent to enhance the MR signal in situ. 
Interestingly, in histology it was observed that some dual-labeled cardiomyocyte-like 
cells were inserted between the host myocardial cells based on cell morphology. 
However, it warrants further investigation to confirm that those transplanted cells are able 
to differentiate into cardiomyocytes (e.g., by using cardiomyocyte-specific staining to 
confirm that some dual-labeled cells are cardiomyoctes).     
4.5 CONCLUSIONS  
This study applied a dual labeling approach to monitor bone marrow-originated 
MSC traffic to the MI site. MPIO labeling produced a hypointensity in MR images and 
enabled noninvasive and temporal cell tracking. The fluorescent labeling allowed for ex 
vivo examination of labeled cells to confirm MRI findings. This technique with dual-
labeling, bone marrow transplantation and multiple imaging modalities provides a unique 
approach to investigate bone-marrow originated stem cells in cardiac remodeling. Once 
the dual-labeled cells infiltrated into the infarcted heart, they maintained their ability to 
divide and differentiate and would contribute to healing process. In this manner, signaling 
pathways for tissue repair by stem cells can be tested and alteration in cell infiltration 
flux can be monitored. Therefore, this technique has a potential application of monitoring 
treatment effects on cell mobilization and infiltration at diseased sites in drug 
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CHAPTER 5  




In this thesis, two different cell labeling strategies were used with MPIO. One is 
the direct injection of MPIO into the animal blood stream to label inflammatory cells de 
novo, and the other is transplantation of MPIO-laden cells into bone marrow after 
labeling these cells in vitro. The former labeling method is a non-specific labeling 
methodology, since all cell types that are able to take up MPIO in vivo would be labeled. 
Nonetheless it has been recognized as an effect cell labeling strategy for labeling 
inflammatory cells, in particular, monocytes/macrophages. Following injection, MPIO 
accumulate primarily in liver, spleen, bone marrow and lymph nodes, organs or tissues 
that are rich in macrophages. However, the pathway of labeled macrophages migrating 
and homing to the pathological heart is beyond the scope of this study and thus is not 
studied. Similarly, how labeled MSC migrate from bone marrow to the infarction site 
also warrants further investigation. It will be helpful to figure out the pathway of labeled 
cells both in a normal condition and during the progress of myocardial infarction. One of 
the important points is to clarify how these labeled cells exchange between the blood and 
monocyte-rich organs, such as bone marrow and spleen. Appendix A and B present some 
preliminary results about the MPIO blood kinetics and the labeled MSC differentiation in 
bone marrow, respectively. However, this preliminary investigation is far less than 
required in order to elucidate a comprehensive circulation pathway for the MPIO-labeled 





The inflammatory cell tracking study demonstrated an inverse linear relationship 
between the MPIO dose and the MR signal intensity at the infarction site. However, 
further study would be recommended to delineate a direct relationship between the 
relative number of labeled cells and the resulted signal intensity. Once a dependable 
curve describing the correspondence between labeled cell number and signal intensity is 
developed, then the number of labeled cells could be directly interpreted from the signal 
intensity in vivo. In a preliminary study, the number of MPIO-labeled cells was counted 
from a transverse histology slice at differential regions including the infarcted 
myocardium, myocardium adjacent to the infarction site and normal myocardium. Then 
these regions were coregistered with their correspondences in the MR image by careful 
observation. A linear regression was performed between the number of labeled cells and 
corresponding signal intensity, through which a moderate linear correlation was acquired 
(Figure 5.1). Certainly far more efforts are warranted in order to delineate a credible 
curve. Furthermore, it must be very careful in dealing with the coregistration between the 
ex vivo histology micrographs and in vivo MR images. One challenge is due to that the 
resolution of micrographs is usually much higher than that of MR images; and the other 
is that the dimension as well as the shape of the heart may change dramatically after ex 















Figure 5.1 Correlation between the MR signal intensity and the number of MPIO-labeled 
cells. MPIO labeled cells are in dark blue in histology after Prussian blue (PB) staining. 
The solid line is the linear regression, and the two dotted lines show 95% confidence 




The MSC tracking study also warrants more investigation, particularly from a 
biological point view. First of all it is necessary to figure out all the cell types that the 
labeled MSC can differentiate into at the infarcted heart. One of the major challenges in 
the treatment of myocardial infarction is to find a way to regenerate the lost myocardium. 
Therefore it is extremely fundamental to clarify whether or not MSC are able to 
differentiate into cardiomyocytes and, if any, how large the cardiomyocyte population 
can be. A couple of labeled cells morphologically resembling cardiomyocytes were 
observed in the infarcted heart (Figure 5.2). However, it is recommended to design and 









Figure 5.2 Heart histology 28 days after MSC transplantation and 14 days after infarction. 
Fluorescent images show the distribution and differentiation of labeled MSC from an 
infarcted heart at 14 days post-infarction. A. Montage cross-section of the heart using 10x 
magnification images from a microscope. White arrows indicate where the GFP+ cells 
(light green) homed to the infarction site. Interestingly, some GFP+ cells accumulated in 
the septal area of the heart (shown by the red arrow). This may indicate potential injury in 
this area. B. White arrows indicate where a large number of GFP+ cells lined the wall of 
a coronary blood vessel. C. GFP+ cells exhibited a fibroblast-like phenotype. MPIO 
particles (in red) were retained in some GFP+ cells. D. Cardiomyocyte-like cell derived 
from labeled MSC inserted between the resident cardiomyocytes. The higher 
magnification images show this cell were duo-labeled with both GFP and MPIO (red spot 








Both studies are to investigate the cell infiltration in the myocardial infarction. No 
matter what cell types, their infiltration should synchronize the progress of myocardial 
infarction. Therefore, any discovery or solution from one study would to some extent 
help the other. The cell labeling is completed before myocardial infarction, through either 
systemic injection or bone marrow transplantation. The labeled cells then home to the 
infarction site through the blood. These two cell implantation methods are distinct from 
the intra-myocardium injection, in which the cell function can be affected by the local 
non-optimal tissue microenvironment. In the future, it would also be interesting to 
systemically connect and compare the results from both studies and to find out potential 
correlations and interactions between the inflammatory cell and MSC infiltration.  
Moreover, the techniques used in these two studies could be applied to drug test. 
For instance, anti-inflammatory drugs (e.g., ACE-Is and Statins) can be applied to test if 
any altered cellular infiltration due to drug treatment can be observed or even be 
quantified. Similarly, drugs that can alter stem cell mobilization can be applied to test the 
enhancement of cell infiltration into the infarcted heart. A preliminary study was 
designed to investigate the potential effect, if any, on MSC infiltration caused by 
granulocyte-colony stimulating factor (GCSF). The signal intensity at the myocardial 
infarction site in GCSF-treated group was significantly lower than that in the untreated 











Figure 5.3 Change of CNR and LVEF due to GCSF injection. Comparison was between 
sham, myocardial infarction without GCSF injection (MI-GCSF) and myocardial 
infarction plus GCSF injection (MI+GCSF) groups. A. Gradual decrease in signal 
intensity was observed in both groups with myocardial infarction, indicating MPIO-
labeled MSC accumulated around the infarction site over time. The MI+GCSF mice 
showed maximal signal attenuation at 14 days post-infarction (D14), indicating more 
MPIO-labeled MSC infiltration compared to the MI-GCSF group. B. Decrease in LVEF 
was observed in both groups with myocardial infarction. While LVEF stabilized after 7 
days post-infarction, the MI+GCSF group showed higher LVEF and thus improved left 
ventricular function compared to the MI-GCSF group. However, the improvement was 
not significant. NS: not significant. D3, D7 and D14: 3, 7 and 14 days post-infarction, 







APPENDIX A   




Before applying iron oxide particles to cell tracking experiments, it is necessary to 
elucidate the blood kinetics of these particles. The blood kinetics of MPIO would 
determine the time interval between the MPIO injection and myocardial infarction 
surgery. To minimize any residual effect caused by MPIO otherwise circulating in the 
blood stream, it is required that myocardial infarction surgery be performed until MPIO 
are completely cleared out of the mouse blood. The short-term blood kinetics of MPIO 
has been demonstrated in chapter 2. The half life of MPIO in the mouse blood stream is 
determined to be less than one minute (see Figure 2.1). Figure A.1 shows the serial 
fluorescent images of blood samples taken at variant time points after MPIO injection. 






Figure A.1 Serial fluorescent images of blood samples. The blood samples (50 µl for 








Figure A.2 Serial fluorescent intensity of blood samples taken at variant time points 
during the myocardial infarction process. SI: signal intensity; 3Hr, D3, and D7 stand for 3 
hours, 3 days and 7 days post-infarction, respectively. The number of animal in each 
group is also noticed below the horizontal axis. The asterisks indicate the difference is 
significant under student t-test.  
 
 
   
To further investigate the long-term MPIO blood kinetics during the process of 
myocardial infarction, blood samples were taken out of mouse blood stream at variant 
time points after the myocardial infarction surgery (3 hours, 3 days and 7 days post-
infarction) and measured using fluorescent imaging. MPIO were injected 7 days before 
myocardial infarction. Blood samples at baseline (6 days after MPIO injection and 1 day 
before surgery) and control samples (blood samples taken from normal animals) were 
also measured as references. Figure A.2 shows the serial fluorescent intensity of blood 
samples for this longitudinal study. Significant difference was obtained between 3 days 
and either control or baseline (P > 0.05), indicating potential enhancement of circulating 
MPIO in the blood stream at 3 days post-infarction. This enhancement may be caused by 





inflammation process. No significant difference was obtained between 3 days or 7 days 
and baseline or control. These findings may suggest that the quantity of circulating 
inflammatory cells maximize at 3 days post-infarction.  
To conclude, the blood kinetics study finds that MPIO has a short half life of 0.73 
minute in the mouse blood stream. Furthermore, the number of circulating MPIO-labeled 
inflammatory cells peaked at 3 days post-infarction. However, there are several 
drawbacks for this study. First, there are only a few time points after the infarction 
surgery (3 hours, 3 and 7 days). It necessitate more time points between 3 hours and 3 
days in order to pinpoint the time when maximal circulating inflammatory cells can be 
found. Second, fluorescent imaging may not have sufficient sensitivity for quantification 
of MPIO-labeled cells in the blood sample. In the case of long-term study, the fluorescent 
intensity of blood samples taken after infarction was in the same order of those at 
baseline or of control. Therefore, the accuracy and reproducibility of the experiment 
results may be severely affected by the stability of the fluorescent imaging system. It is 
suggested using more accurate methods, such as flow cytometry, to quantify the absolute 
number of MPIO-labeled inflammatory cells in the blood sample. In these methods, 
either the Suncoast Yellow fluorescence or the magnetite core in MPIO can be used as a 






APPENDIX B   




It is necessary to investigate their capability of proliferation and differentiation of 
before and after labeled MSC are transplanted into the bone marrow. Otherwise the 
experiment cannot be carried on if the labeled cells lose viability. In the cell culture, the 
serial MSC differentiation MSC was observed at variant time points after they were 
labeled with MPIO. The labeled cells retained their capability of proliferation. During the 
7-day observation period, a portion of cells were able to maintain the MPIO. Figure B.1 
demonstrated that the daughter cells maintained MPIO for at least 7 days. During the 
process of cell division, MPIO are split into the descendant daughter cells. Some 
descendant cells will eventually lose MPIO since only a finite number of particles are 
included in the original MSC. Figure B.2 demonstrates the number of labeled cells at 
variant generations. Originally all the twenty MSC were labeled with MPIO, each MSC 
with variant numbers of MPIO. The labeled cells increased along with cell division, with 
~120 cells labeled at 7 days. The number of total cells including both labeled and 
unlabeled MSC increases dramatically during the 7-day observation period. The portion 
of labeled cells decreased. The number of free MPIO altered with cell division, indicating 






        
Figure B.1 Division of a single labeled MSC. Each row represents an observation date 
and D2, D3, D4 and D7 stand for 2, 3, 4 and 7 days after cell labeling. The green color is 











After transplantation into bone marrow, the labeled MSC retain their capability of 
proliferation and differentiation. In Figure B.3, the viable GFP+ cells can be observed in 
the marrow space after transplantation. At one hour post-transplantation, the cells 
scattered around in the bone marrow space. At 4 weeks post-transplantation, the number 
of GFP labeled cells increased dramatically, indicating the proliferation of transplanted 
cells. The GFP+ cells were flattened on the surface of trabeculae bone (tr), suggesting the 
fusion of GFP+ cells with the microenvironment. Micro-computed tomography (Micro-
CT) further demonstrates the formation of new bone in the hinder leg of the animal with 
labeled MSC transplantation, whereas none was observed in the hinder leg of the animal 
with saline injection. These findings proved that the labeled MSC retain their capability 
of proliferation and differentiation after they are transplanted into the bone marrow, 





Figure B.3 MSC proliferation after transplantation into the bone marrow. A, B, C are 
imaging of only the GFP channel, and D, E, F imaging of the bright field. tr stands for 
trabecular bone. The black arrows in F point to the flattened GFP+ cells on the surface of 
trabecular bone. In panel A-F, the MSC were labeled only with GFP and therefore no 










C.1 STRUCTURE AND FUNCTION  
The CardiProc program was developed in MATLAB environment. Currently, it 
can only be run within MATLAB.  “CardiProc” is taken from the phrase “Cardiac Image 
Processing”, and therefore this program is used in particular for the analysis of cardiac 
images. The author has used this program to analyze cardiac magnetic resonance images. 
The Medical College of Georgia Office of Technology Transfer has disclosed the 
intellectual property of this program as a provisional patent. 
CardiProc program consists of seven components in its menu list, including File, 
ROI, Process, Data, Segment, Histogram, and Statistic. Each menu is for a separate 
function.      
 
 




The File menu is for opening and saving functions. There are 5 submenus: Open, 
Save, Save as, Save all and Save statistics. Users can open raw data, image sequence, 
mask/region of interest (ROI), as well as to localize any frame of an opened image 





additional saving functions are accomplished by Save all and Save statistics. Save all 
can save all the data the user has analyzed into a .Mat file. These files can be used for the 
simple statistical analysis in the menu Statistic.  
 
Figure C.2 File menu 
 
The ROI menu is for ROI analysis. Users can manually draw a new ROI after 
clicking New ROI. Clicking Load ROI will load a saved ROI into the current image. 
Save ROI allows users to save the current ROI after they have named it. Users can use 
Combine as mask to convert the two most recently activated ROIs into a mask, which 
allows to process a partial image covered by the mask, for instance, the left ventricular 
wall.    





The Process menu consists of two submenus. Under MI center, user can localize 
the center of the myocardial infarction area, or any point that user is interested in. Once 
the center is localized, the program will convert the left ventricular wall into a standard 
ring after the user clicks the Standard heart submenu. This ring with a width of 20 
pixels and a circumference of 100 pixels is referred as standard heart in this instruction.     
The Data menu is used to calculate the thickness of the masked left ventricular 
wall, and to fit the 360-degree view of thickness data into a curve, which usually is a step 
function that can differentiate the myocardial infarction region and the adjacent regions. 
This is done by Calculate thickness data and Fit thickness respectively. The Open 
thickness data is used to import a saved thickness data file into the program. 
Figure C.5 Data menu. 








The Segment menu is for segmentation of the left ventricular wall. Users can 
click Uniform submenu to segment the left ventricular wall into ten segments uniformly, 
or they can click Nonuniform to segment it into one ring composed of one myocardial 
infarction region, two adjacent regions and four normal myocardium regions. In this 
instruction the uniformly segmented and nonuniformly segmented left ventricular wall 
are referred as uniform heart and nonuniform heart, respectively.    
Figure C.6 Segment menu. 
 
 
The user can acquire the statistical data as well as histogram for a specified ROI 
in Histogram menu. Clicking the Histogram submenu will pop out the HistGUI 
window. By clicking Acquire histogram the program will provide the statistics of the 
signal intensities within the current ROI. Also, a histogram will appear at the bottom, x-
axis being the value of gray level (0-255) and y-axis being the number of pixels 
corresponding to each value. The user can save the data by clicking Append after they 















The Statistic menu is for batch processing of a data group. First, users have to 
load a file containing individual data files (.Mat format). Then they can click Standard 
heart to obtain a standard heart standing for the average of all the individual data in the 
file. There will be two images displayed in the window, one is the mean data, and the 
other is the standard deviation data. Similarly, the user can also obtain an averaged 
uniform heart or nonuniform heart by using Uniform segment or Nonuniform segment, 
















Figure C.10 The image interface for localization of the center of the infarction region. 






























C.3 PROGRAM CODE 
function varargout = CardiProc(varargin) 
% CARDIPROC M-file for CardiProc.fig 
%      CARDIPROC, by itself, creates a new CARDIPROC or raises the existing 
%      singleton*. 
% 
%      H = CARDIPROC returns the handle to a new CARDIPROC or the handle to 
%      the existing singleton*. 
% 
%      CARDIPROC('CALLBACK',hObject,eventData,handles,...) calls the local 
%      function named CALLBACK in CARDIPROC.M with the given input arguments. 
% 
%      CARDIPROC('Property','Value',...) creates a new CARDIPROC or raises the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before CardiProc_OpeningFunction gets called.  An 
%      unrecognized property name or invalid value makes property application 
%      stop.  All inputs are passed to CardiProc_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
 
% Edit the above text to modify the response to help CardiProc 
 
% Last Modified by GUIDE v2.5 04-Aug-2009 20:37:31 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @CardiProc_OpeningFcn, ... 
                   'gui_OutputFcn',  @CardiProc_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 




    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 







% --- Executes just before CardiProc is made visible. 
function CardiProc_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to CardiProc (see VARARGIN) 
 
% Choose default command line output for CardiProc 
handles.output = hObject; 
handles.Flag_MICenter=0; 
% Update handles structure 
guidata(hObject, handles); 
 




% --- Outputs from this function are returned to the command line. 
function varargout = CardiProc_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Get default command line output from handles structure 
varargout{1} = handles.output; 
 
%********************************************************************** 




%function to find the center of mass 
%------------------------------------------------------------------------- 
function COM=FindCOM(Mask) 
%this function find the Center of Mass (COM) of the mask image 
%Mask is the mask image used for mask and also to calculate the COM; COM is 
%a vector composed of the row and column number of the COM.  
AntiMask=~Mask;%use the complemental image so as to find the COM of the Left 
Ventrical Chamer,not the LVW. 






[r,c]=find(L==2);%find the row vector (r) and column vector (c) of the connected 






%function to convert image in rectangular coordinates to polar coordinates 
%------------------------------------------------------------------------- 
function PolF = DisinPol(f,com) 
%The function DisinPol draw and display the image f in polar coodinates 
%The input is the image F in cartisian system, center of the mass COM, and 
%the angle off the vertical line OFFANG. 
%The convertion starts from 9 clock direction and rotate clockwise 
 
th = linspace(-pi,pi,101); 
r = linspace(0,50,101); 
%Set the matrix=101x101 
X = -50:1:50; 
Y = -50:1:50; 
% Specifiy the center point or the origin for the conversion 
Xc=com(1); 
Yc=com(2); 




[R, TH] = meshgrid(r,th); 
%To check THETA is -pi to pi. 
idx=find(TH(:)>pi); 
if(~isempty(idx)) 




   TH(idx)=TH(idx)+2*pi; 
end 
% Convert the pair to cartesian 
[XI, YI] = pol2cart(TH, R); 
% Interpolate the points to find the new data points 
ZI = interp2(X, Y, f, XI, YI); 
% Change the data in (Theta,R)format 








%Convert into CARTISIAN coordinates from POLAR coordinates  
%------------------------------------------------------------------------- 
function CartIm=DisinCart(PolIm) 
%This function convert the polar image to cartisian system 









%Order: theta first, r second 








Aparam = param(1); 
Bparam = param(2); 
Cparam = param(3); 
aparam = param(4); 
bparam = param(5);     
cparam = param(6); 
dparam = param(7); 
 r = input; 
azslope1 = - (Aparam.*1 - Cparam.*1)/ (bparam.*1 - aparam.*1); %first adjacent zone 
slope 
azslope2 =(Bparam.*1 - Cparam.*1)/ (dparam.*1 - cparam.*1); %second adjacent zone 
slope 
azconst1 = Aparam.*1 - (azslope1 * aparam.*1); 
azconst2 = Cparam.*1 - (azslope2 * cparam.*1); 
azcurve1 = ((azslope1*r) + azconst1); 
azcurve2 = ((azslope2*r) + azconst2); 
azcurveregion1 = (Heaviside(r-(aparam.*1))-Heaviside(r-(bparam.*1))); 
indexrange1 = find(azcurveregion1 == 0); 
azcurve1(indexrange1) = 0; 
azcurveregion2 = (Heaviside(r-(cparam.*1))-Heaviside(r-(dparam.*1))); 
indexrange2 = find(azcurveregion2 == 0); 
azcurve2(indexrange2) = 0; 





output = (Aparam.*1)*(Heaviside(r-0)-Heaviside(r-(aparam.*1))) ... 
        + azcurve1 +(Cparam.*1)*(Heaviside(r-(bparam.*1))-Heaviside(r-(cparam.*1))) ... 
        + azcurve2 + (Bparam.*1)*(Heaviside(r-(dparam.*1))-Heaviside(r-101.1)); 









function Open_Callback(hObject, eventdata, handles) 
% hObject    handle to Open (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function Save_Callback(hObject, eventdata, handles) 
% hObject    handle to Save (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%If no file is open, catch an error and return 
   try 
   pathname=handles.LastPathname; 
   filename=hanles.LastFilename; 
   catch 




   return 
elseif ~isempty(strfind(filename,'.tif')) 
   try 
      LastFigure=handles.LastFigure; 
   catch 
      errordlg('You do not have any figure to save!'); 
      return 
   end 
   imwrite(LastFigure,File,'tif'); 
elseif ~isempty(strfind(filename,'.mat')) 
    try 
       LastROI=handles.LastROI; 
   catch 





      return 
   end        
    save (File, 'LastROI'); 
elseif ~isempty(strfind(filename,'.xls')) 
    try 
       ThDataT=handles.ThData; 
       FitThDataT=handles.FitThData; 
       FitParDataT=handles.FitParData; 
    catch 
      errordlg('You do not have any data to save!'); 
      return 
    end 
    xlswrite(File,ThDataT,1,'a1');%save the thickness data 
    xlswrite(File,FitThDataT, 1,'b1');%save the fitted data 
    xlswrite(File,FitParDataT,1,'c1');%save the fitting parameters 
else 
    return; 
end 





function SaveAs_Callback(hObject, eventdata, handles) 
% hObject    handle to SaveAs (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
[filename, pathname]=uiputfile({'*.tif','Tiff image(*.tif)';... 
    '*.mat','MAT-file(*.mat)';... 
    '*.xls','Excel(*.xls)'},'Save as'); 
File=fullfile(pathname,filename); 
if isequal([filename,pathname],[0,0]) 
   return 
elseif ~isempty(strfind(filename,'.tif')) 
   try 
      LastFigure=handles.LastFigure; 
   catch 
      errordlg('You do not have any figure to save!'); 
      return 
   end 
   imwrite(LastFigure,File,'tif'); 
elseif ~isempty(strfind(filename,'.mat')) 
    try 
       LastROI=handles.LastROI; 





      errordlg('You do not have any ROI to save!'); 
      return 
   end        
    save (File, 'LastROI'); 
elseif ~isempty(strfind(filename,'.xls')) 
    try 
       ThDataT=handles.ThData; 
       FitThDataT=handles.FitThData; 
       FitParDataT=handles.FitParData; 
    catch 
      errordlg('You do not have any data to save!'); 
      return 
    end 
    xlswrite(File,ThDataT,1,'a1');%save the thickness data 
    xlswrite(File,FitThDataT, 1,'b1');%save the fitted data 
    xlswrite(File,FitParDataT,1,'c1');%save the fitting parameters 
else 










function File_Callback(hObject, eventdata, handles) 
% hObject    handle to File (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function RawData_Callback(hObject, eventdata, handles) 
% hObject    handle to RawData (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
[filename,pathname]=uigetfile({'*.*','All files(*.*)'},... 
    'Select file you want to open'); 
%if "Cancel" is selected then return 
if isequal([filename,pathname],[0,0]) 
    return 
%otherwise construct the full file name, and check and load the file 
  






        %update this file as the current file 
        File=fullfile(pathname,filename); 
        handles.LastFile=File; 
        %open the file  
        fid=fopen(File,'r','l'); %open the file filename. 
        fidmix=fread(fid,inf,'int16'); %read the file fid 
        fidmix=reshape(fidmix,256,256); %reshape the 1-dimension array 
        Image=mat2gray(fidmix);%convert matrix to inten the sity image 
        Image=Image';%get the image matrix by transpose 
        handles.LastFigHdl=figure; 
        imshow(Image) 
        hold on 
        truesize([600 600]); 
        handles.LastFigure=Image; 
        guidata(handles.figure1,handles) 
%if the file is not '2dseq',display error message 
else  
    errordlg('Not a valid RAW DATA file','Open file error') 
end 
     
% -------------------------------------------------------------------- 
function ROI_Callback(hObject, eventdata, handles) 
% hObject    handle to ROI (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function NewROI_Callback(hObject, eventdata, handles) 
% hObject    handle to NewROI (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
%[ROI, ROI_C, ROI_R]=roipoly(handles.LastFigure); 
%h=gcf; 
try 
    figure(handles.LastFigHdl); 
catch 
    errordlg('Make sure the image is open!'); 
    return 
end 
%figure(handles.LastFigHdl) 
hold on  
imshow(handles.LastFigure,[0.04 0.6]); 
%Draw the ROI 







%Draw ROI polygon 
catch 






%FACECOLOR,FACEALPHA,EDGECOLOR,EDGEALPHA could be modified to 
change the 
%color and transparency of the surface. 
 






function LoadROI_Callback(hObject, eventdata, handles) 
% hObject    handle to LoadROI (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%To load the ROI data 
[filename, pathname]=uigetfile({'*.mat','MAT-file(*.mat)';... 
    '*.*','All files(*.*)'},'Load ROI'); 
if isequal([filename,pathname],[0,0]) 
    return 
else 
    File=fullfile(pathname,filename); 








function SaveROI_Callback(hObject, eventdata, handles) 
% hObject    handle to SaveROI (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%The ROI is saved as matrix in name of LastROI into the matfile. 
 





                    'Save ROI',... 
                    'ROI_Inside','ROI_Outside','Others',... 
                    'Others'); 
switch ButtonName, 
    case 'ROI_Inside', 
        try 
           ROI_Inside=handles.LastROI; 
        catch 
           errordlg('Please acquire ROI first!'); 
           return 
        end 
        LastROI=ROI_Inside; 
        handles.ROI_Inside=ROI_Inside; 
    case 'ROI_Outside', 
        try 
        ROI_Outside=handles.LastROI; 
        catch 
           errordlg('Please acquire ROI first!'); 
           return 
        end         
        LastROI=ROI_Outside; 
        handles.ROI_Outside=ROI_Outside; 
    case 'Others',%save roi and return 
        try 
           LastROI=handles.LastROI; 
        catch 
           errordlg('Please acquire ROI first!'); 
           return 
        end            
        [filename, pathname]=uiputfile({'*.mat','MAT-file(*.mat)';... 
                    '*.*','All files(*.*)'},'Save ROI as'); 
        if isequal([filename,pathname],[0,0]) 
            return 
        else 
            File=fullfile(pathname,filename); 
            save (File, 'LastROI'); 
        end 
        handles.LastPathname=pathname; 
        handles.LastFilename=filename; 
        %Need guidata update 
        return; 
    case '', 











function Combine_Callback(hObject, eventdata, handles) 
% hObject    handle to Combine (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
%If handles.ROI_Inside and handles.ROI_Outside, catch a error 
%Combine ROI_Outside and ROI_Inside to get the ROI_LVW 
try 
    ROI_Inside=handles.ROI_Inside; 
    ROI_Outside=handles.ROI_Outside; 
catch 
    errordlg('Please acquire ROI first!'); 









function Mask_Callback(hObject, eventdata, handles) 
% hObject    handle to Mask (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
[filename,pathname]=uigetfile({'*.mat','MAT-file';... 
    '*.*','All files(*.*)'},'Select file you want to open'); 
%if "Cancel" is selected then return 
if isequal([filename,pathname],[0,0]) 
    return 
%otherwise construct the full file name, and check and load the file 
  
%if the file is '2dseq', open it. 
elseif strcmp(filename,'2dseq') 
       %update this file as the current file 
       File=fullfile(pathname,filename); 
       handles.LastFile=File; 
       %open the file  
       fid=fopen(File,'r','l'); %open the file filename. 
       %remember the viewport data from Bruker is int8 format. 
       fidmix=fread(fid,inf,'int8');  
       %reshape the 1-dimension array to a 256x256 matrix 





       Mask=mat2gray(fidmix); %convert matrix to inten the sity image. Values [0,1] 
       Mask=Mask'; %get the image matrix by transpose 
       %Convert the Mask image to logic image.  
       Mask=Mask>1e-10; %use 1e-10 instead of 0. 
%if the file is Mat-file, load it. 
elseif ~isempty(strfind(filename,'.mat')) 
       File=fullfile(pathname,filename); 
       load(File, 'LastROI'); 
       Mask=LastROI; 
else %if the file is not '2dseq' or '.mat',display error message 
  












function Overlay_Callback(hObject, eventdata, handles) 
% hObject    handle to Overlay (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function Data_Callback(hObject, eventdata, handles) 
% hObject    handle to Data (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function OpenThicknessData_Callback(hObject, eventdata, handles) 
% hObject    handle to OpenThicknessData (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
[filename,pathname]=uigetfile({'*.xls','Excel(*.xls)';'*.*','All files(*.*)'},... 
    'Select file you want to open'); 
%if "Cancel" is selected then return 
if isequal([filename,pathname],[0,0]) 
    return 






%if the file is '2dseq', open it 
elseif ~isempty(strfind(filename,'.xls')) 
        %update this file as the current file 
        File=fullfile(pathname,filename); 
        handles.LastFile=File; 
        %open the file  
        Data=xlsread(File,1,'A1:A101'); 
        %Convert the column data to row data  
        handles.LastData=Data'; 
        guidata(hObject,handles) 
        %handles.LastMask 
%if the file is not '2dseq',display error message 
else  










function CalculateThicknessData_Callback(hObject, eventdata, handles) 
% hObject    handle to CalculateThicknessData (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Construct a questdlg to check if the MI center is already located 
choice = questdlg('Have you localized the MI center?', ... 
 'Please locate MI center before calculation', ... 
 'Yes','No','Cancel','Cancel'); 
% Handle response 
switch choice 
    case 'Yes' 
        if(~handles.Flag_MICenter) 
            errordlg('Sorry, please chose MI center first!') 
            return; 
        end 
        OffAng=handles.OffAng;    
    case 'No' 
        return; 
    case 'Cancel' 










%First to find the center of mass of the Left Ventricle 
COM=FindCOM(handles.LastMask); 
%Then to convert the image into polar coordinates 
PolF=DisinPol(Image,COM);%initially set the offang to be 0. 
%Then calculate the thickness data 
ThickData=sum(PolF>1e-10); 
%Circulate Shift (25~101/4~90 degree) elements to localize the MI center 








function FitThickness_Callback(hObject, eventdata, handles) 
% hObject    handle to FitThickness (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
Theta=1:1:101; 
%If handles.LastData does not exist, catch a eorror 
try 
    ThData=handles.LastData; 
catch 
    errordlg('Please acquire thickness data first!'); 
    return 
end 
ThData=ThData*30/256/2;%In coordinate convertion, 50/101~1/2 
%Define options for the least square curve fitting 
options=optimset('MaxFunEvals',1000,'TolFun',1e-100,'TolX',1e-100,'MaxIter',1000); 
 
    igA=1.5; 
    igB=1.5; 
    igC=0.5; 
    iga=20; 
    igb=40; 
    igc=50; 
    igd=80; 
    InitialConditions=[igA,igB,igC,iga,igb,igc,igd]; 
















azslope1 = - (Aparam.*1 - Cparam.*1)/ (bparam.*1 - aparam.*1); %first adjacent zone 
slope 
azslope2 =(Bparam.*1 - Cparam.*1)/ (dparam.*1 - cparam.*1); %second adjacent zone 
slope 
azconst1 = Aparam.*1 - (azslope1 * aparam.*1); 
azconst2 = Cparam.*1 - (azslope2 * cparam.*1); 
azcurve1 = ((azslope1*r) + azconst1); 
azcurve2 = ((azslope2*r) + azconst2); 
azcurveregion1 = (Heaviside(r-(aparam.*1))-Heaviside(r-(bparam.*1))); 
azcurve1(azcurveregion1 == 0) = 0; 
azcurveregion2 = (Heaviside(r-(cparam.*1))-Heaviside(r-(dparam.*1))); 
azcurve2(azcurveregion2 == 0) = 0; 
FitData = (Aparam.*1)*(Heaviside(r-0)-Heaviside(r-(aparam.*1))) ... 
        + azcurve1 +(Cparam.*1)*(Heaviside(r-(bparam.*1))-Heaviside(r-(cparam.*1))) ... 
        + azcurve2 + (Bparam.*1)*(Heaviside(r-(dparam.*1))-Heaviside(r-101.1)); 




DataWrite={'Parameter','A','B','C','a','b','c','d','MI Center','Rotate Angle';... 
    'Value',Aparam,Bparam,Cparam,aparam,bparam,cparam,dparam,MICenter,RotAng}; 
 




axis([0 360 0 2]); 
hold on 
plot(Angle,FitData,'r-.','LineWidth',4,'MarkerFaceColor',... 
    'r','MarkerEdgeColor','r','MarkerSize',10); 
xlabel('Radial angle (degree)'); 















%this function is to localize the MI center 
%--------------------------------------------------------------------- 
function MICenter_Callback(hObject, eventdata, handles) 
% hObject    handle to MICenter (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
try 
   Mask=handles.LastMask; 
   Image=handles.LastFigure; 
catch 
   errordlg('Please acquire MASK first!'); 
   return 
end 
Image=Image.*Mask; 
%This serves as a marker to see the relative geometry during coordinates conversion.  
%Image(170:180,93:200)=0; 
 
%Find the center fo mass(COM) 
%Can improve by define handles.COM as guidata 
com=FindCOM(Mask); 
 
%The window will allow us to pick the center of the MI, approximately. 
dim=[256 256]; 
%Define a flag to determine the termination of loop 
     




plot(com(2), com(1), 'Marker','o','MarkerFaceColor',... 




flg=0;%Flag to determine when to terminate the loop. 
flg1=0;%Flag to dtermine if the user has performed left-click to locate  
       %the MI center. Display a error message if Not. 
ventr=zeros(1,2); 
while(flg==0) 
    %seems the com is localized in coordernates 256x256, although the 





    COLORMAP('default'); 
    F=gcf; 
    g=get(F); 
    imgpos=get(g.CurrentAxes,'Position'); 
    set(F,'name',... 
        'Left click on the center of the MI,right click to accept or left click to clear.'); 
    % Choose the center of MI ... 
    waitforbuttonpress; 
    SelnType = get(gcf,'SelectionType'); 
    if(strcmp(SelnType,'normal')) 
        get(F,'Units'); 
        set(F,'Units','Pixels'); 
        pos=get(F,'Position'); 
        loc=get(F,'CurrentPoint'); 
        ventr=round([dim(2)*(pos(4)-(loc(2)+imgpos(2)*pos(4)))/(pos(4)*imgpos(4)) ... 
                     dim(1)*(loc(1)-imgpos(1)*pos(3))/(pos(3)*imgpos(3))]); 
         
        imshow(Image,[min(Image(:)) max(Image(:))]); 
        truesize([600,600]); 
        hold on 
        plot(com(2), com(1), 'Marker','o','MarkerFaceColor',... 
            'r','MarkerEdgeColor','r','MarkerSize',10); 
        plot(ventr(2), ventr(1), 'Marker','*','MarkerFaceColor',... 
            'c','MarkerEdgeColor','c','MarkerSize',10); 
        flg1=1; 
    %end 
    % Now, agree or not? if YES, right click to terminate the procedure 
    %waitforbuttonpress; 
    %SelnType = get(gcf,'SelectionType'); 
    elseif(strcmp(SelnType,'alt'))&&flg1==1 
        flg=1; 
        msgbox('The MI center has been chosen'); 
    else %(strcmp(SelnType,'alt'))&&flg1==0 
        msgbox('Please start "MI center submenu" again and chose the MI center'); 
        return; 
        %Return the focus to the figure created previously 
        %uicontrol(h); 
        %Replot the original image   
    end             
end           
 










%Update the data in handles 
handles.COM=com; 
handles.OffAng=OffAng; 





function Process_Callback(hObject, eventdata, handles) 
% hObject    handle to Process (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function StandardHeart_Callback(hObject, eventdata, handles) 
% hObject    handle to StandardHeart (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%To get the masked image (LVW) 
try 
   Image=handles.LastFigure; 
   Mask=handles.LastMask; 
catch 
   errordlg('Please acquire IMAGE and MASK first!'); 
   return 
end 
Image=Image.*Mask; 






    errordlg('Please locate MI center first!'); 
    return 
end 
%To remove the NaN from the matrix 
PolImg(isnan(PolImg))=0; 
%To get the thickness data 
ThData1=sum(PolImg>1e-10); 










%Interpolate the LVW band in polar map to get the standard heart. 




    NonZero=find(PolImg(:,j)>1e-6); 
    L=length(NonZero); 
    X=1:1:L; 
    %Interpolate the L non-zero pixels to 20 pixels 
    Y=linspace(1,L,20); 
    NewEl=interp1(X,PolImg(NonZero,j),Y); 
    %Change corresponding values in Output 
    Output(61:80,j)=NewEl; 
end 
















function Segment_Callback(hObject, eventdata, handles) 
% hObject    handle to Segment (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function Uniform_Callback(hObject, eventdata, handles) 
% hObject    handle to Uniform (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
%To get the masked image (LVW) 
try 
   Image=handles.LastFigure; 






   errordlg('Please acquire IMAGE and MASK first!'); 
   return 
end 
Image=Image.*Mask; 
%To display the masked image (LVW)in polar coordinates 
try 
   COM=handles.COM; 
catch 
    errordlg('Please locate the MI center first!'); 




%To remove the NaN from the matrix 
PolImg(isnan(PolImg))=0; 
%To get the thickness data 
ThData=sum(PolImg>1e-10); 
%To get the Signal Intensity data 
SIData=sum(PolImg)./ThData; 




%Make MI localized at the center of the SI data 
SIData=(circshift(SIData',ColShift))'; 
 
%To get the lower border every 10 colums 
UpLtRow=zeros(1,101); 
for j=1:10:101 
    UpLtRow(j)=find(PolImg(:,j)>1e-10, 1 ); 
    %The row coordinates for every 10 columns 
end 
 
















%row is the upper border and the 2nd row is the lower border 
Border=zeros(2,101); 
for i=1:10:91 
    for j=0:1:9 
    Border(1,i+j)=round(UpLtRow(i)*((10-j)/10)+UpLtRow(i+10)*(j/10)); 
    Border(2,i+j)=round((UpLtRow(i)+ThData(i))*((10-j)/10)... 
        +(UpLtRow(i+10)+ThData(i+10))*(j/10)); 





%To re-plot the Polar Image with UpLtRow,ThData,and MeanVal 
NewPolImg=zeros(101,101); 
for j=1:1:100 



























function Nonuniform_Callback(hObject, eventdata, handles) 
% hObject    handle to Nonuniform (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 






%Pass the fitting parameters 
FitParam=handles.FitParam;%FitParam contains 4 valuses,a,b,c,d 










%This code to make all the elements are integers. 
for i=1:1:8 
    if Marker(i)<1 
        Marker(i)=1; 
    end 
end 
 







%Get the image and corresponding figure 
try 
   Image=handles.LastFigure; 
   Mask=handles.LastMask; 
catch 
   errordlg('Please acquire IMAGE and MASK first!'); 
   return 
end 
Image=Image.*Mask; 
%To display the masked image (LVW)in polar coordinates 
try 
   COM=handles.COM; 
catch 
    errordlg('Please locate the MI center first!'); 











%To get the thickness data used for calculating mean SI value 
ThData1=sum(PolImg>1e-10); 
 
%To get the Signal Intensity data 
SIData=sum(PolImg)./ThData1; 
%Shift the data to re-locate the MI center at the bottom 
ColShift=round(OffAng*101/(2*pi)); 






%To get the lower border every 10 colums 
UpLtRow=zeros(1,101); 
for j=1:1:8 
    UpLtRow(Marker(j))=find(PolImg(:,Marker(j))>1e-10, 1 ); 
    %The row coordinates for every 10 columns 
end 
 








%To fit the border of the LVW band and save it in 2-D array BORDER, the 1st 
%row is the upper border and the 2nd row is the lower border 
Border=zeros(2,101); 
for i=1:1:7 
    for j=Marker(i):1:Marker(i+1) 
    Border(1,j)=round(UpLtRow(Marker(i))*((Marker(i+1)-j)/(Marker(i+1)-Marker(i)))... 
        +UpLtRow(Marker(i+1))*(j-Marker(i))/(Marker(i+1)-Marker(i))); 
    Border(2,j)=round(((UpLtRow(Marker(i))+ThData(i))*(Marker(i+1)-j)... 
        +(UpLtRow(Marker(i+1))+ThData(i+1))*(j-Marker(i)))/(Marker(i+1)-Marker(i))); 
    
    end 
end 
 







    for j=Marker(i):1:Marker(i+1) 
    NewPolImg(Border(1,j):Border(2,j),j)=MeanVal(i); 
    end 
end 
 
%To make sure the MI locate at the bottom, shift back 
NewPolImg=(circshift(NewPolImg',25))'; 






















function Histogram_Callback(hObject, eventdata, handles) 
% hObject    handle to Statistic (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 






function Histogram_Callback_Previous(hObject, eventdata, handles) 
% hObject    handle to Statistic (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 







%    'papersize',[8 11]); 
Panel_AcqHist = uipanel('Title','Acquire histogram','FontSize',12,... 
                'Position',[0.01 0.75 0.98 0.25]); 
 
Button_AcqHist = uicontrol('Parent',Panel_AcqHist,... 
    'Callback',@Button_AcqHist_Callback1,... 
    'String','Acquire histogram','Position',[5 50 100 30]);  
 
Text_Mean = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','Mean','HorizontalAlignment','center',... 
    'Position',[110 50 100 30],'Tag','TextMean');   
Text_MeanVal = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','MeanVal','HorizontalAlignment','center',... 
    'Position',[110 20 100 30],'Tag','TextMeanVal');   
Text_Stdev = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','Standard deviation','HorizontalAlignment','center',... 
    'Position',[210 50 100 30]); 
Text_StdevVal = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','StdevVal','HorizontalAlignment','center',... 
    'Position',[210 20 100 30]); 
Text_Area = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','Area','HorizontalAlignment','center',... 
    'Position',[310 50 100 30]); 
Text_AreaVal = uicontrol('Parent',Panel_AcqHist,'style','text',... 
    'String','AreaVal','HorizontalAlignment','center',... 
    'Position',[310 20 100 30]); 
            
Panel_SaveHist =uipanel('Title','Save histogram','FontSize',12,... 
                'Position',[0.01 0.59 0.98 0.2]); 
Text_DefineList = uicontrol('Parent',Panel_SaveHist,'style','text',... 
    'String','Define list','HorizontalAlignment','center',... 
    'Position',[5 25 100 30]);             
Edit_DefineList = uicontrol('Parent',Panel_SaveHist,'style','edit',... 
    'String','input pathway here','HorizontalAlignment','center',... 
    'Position',[110 35 300 25]);              
Button_Browse = uicontrol('Parent',Panel_SaveHist,... 
    'Callback','Button_Browse_Callback',... 
    'String','Browse','Position',[415 35 100 25]);   
 
Text_NameHist = uicontrol('Parent',Panel_SaveHist,'style','text',... 
    'String','Name histogram','HorizontalAlignment','center',... 
    'Position',[5 1 100 30]);             
Edit_NameHist = uicontrol('Parent',Panel_SaveHist,'style','edit',... 
    'String','input name here','HorizontalAlignment','center',... 
    'Position',[110 5 300 25]);              





    'String','Append','Position',[415 5 100 25]);  
                    
Axes_Hist=axes('Position',[0.05 0.05 0.94 0.52],'XLim',[0 256],... 








%Compute the histogram of the pixels in the ROI 
%Histogram=imhist(Image(ROI)); 
%Obtain the number of pixels in the ROI 
%npix=sum(ROI(:)) 





function Statistic_Callback(hObject, eventdata, handles) 
% hObject    handle to Statistic (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function StdHeart_Callback(hObject, eventdata, handles) 
% hObject    handle to StdHeart (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 






hold on, colormap('jet'),colorbar,hold off; 
subplot(1,2,2),imshow(StdHtStdev,[min(StdHtStdev(:))... 














function UnifmSegmt_Callback(hObject, eventdata, handles) 
% hObject    handle to UnifmSegmt (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 






%Get the mean data  
ThDataMean=mean(ThDataAll,2); 





%Produce the new average segmentation image 
Border=zeros(2,101); 
for i=1:10:91 
    for j=0:1:9 
    Border(1,i+j)=round(UpLtRowMean(i)*((10-j)/10)+UpLtRowMean(i+10)*(j/10)); 
    Border(2,i+j)=round((UpLtRowMean(i)+ThDataMean(i))*((10-j)/10)... 
        +(UpLtRowMean(i+10)+ThDataMean(i+10))*(j/10)); 









    NewPolImgMean(Border(1,j):Border(2,j),j)=MeanValMean(ceil(j/10)); 



























function NonunifmSegmt_Callback(hObject, eventdata, handles) 
% hObject    handle to NonunifmSegmt (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 














%To fit the border of the LVW band and save it in 2-D array BORDER, the 1st 
%row is the upper border and the 2nd row is the lower border 
Border=zeros(2,101); 
for i=1:1:7 
    for j=MarkerMean(i):1:MarkerMean(i+1) 
    Border(1,j)=round((UpLtRowMean(MarkerMean(i))*(MarkerMean(i+1)-j)... 
        +UpLtRowMean(MarkerMean(i+1))*(j-MarkerMean(i)))/... 
        (MarkerMean(i+1)-MarkerMean(i))); 
    
Border(2,j)=round(((UpLtRowMean(MarkerMean(i))+ThDataMean(i))*(MarkerMean(i+
1)-j)... 
        +(UpLtRowMean(MarkerMean(i+1))+ThDataMean(i+1))*(j-MarkerMean(i)))/... 
        (MarkerMean(i+1)-MarkerMean(i))); 
    
    end 
end 
 








    for j=MarkerMean(i):1:MarkerMean(i+1) 
    NewPolImgMean(Border(1,j):Border(2,j),j)=MeanValMean(i); 
    NewPolImgStdev(Border(1,j):Border(2,j),j)=MeanValStdev(i); 
    end 
end 
 









   hold on, colormap('jet'),colorbar,hold off; 
subplot(1,2,2),imshow(NuSegHtStdev,[min(NuSegHtStdev(:)) 
max(NuSegHtStdev(:))]),... 









function DefineList_Callback(hObject, eventdata, handles) 
% hObject    handle to Histogram (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
[filename, pathname]=uiputfile({'*.xls','Excel(*.xls)'},... 
    'Define an Excel file'); 
if isequal([filename,pathname],[0,0]) 
    return 
else 
    File=fullfile(pathname,filename); 











function GetHistgrm_Callback(hObject, eventdata, handles) 
% hObject    handle to GetHistgrm (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%Get the data from guidata 
ROI=handles.LastROI; 
%Compute the histogram of the pixels in the ROI 
Histogram=imhist(f(ROI)); 




function SaveHistgrm_Callback(hObject, eventdata, handles) 
% hObject    handle to SaveHistgrm (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function Sequence_Callback(hObject, eventdata, handles) 
% hObject    handle to Sequence (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 





    'Select raw sequence data you want to open'); 
%if "Cancel" is selected then return 
if isequal([filename,pathname],[0,0]) 
    return 
%otherwise construct the full file name, and check and load the file 
  
%if the file is '2dseq', open it 
elseif strcmp(filename,'2dseq') 
      File=fullfile(pathname,filename); 
      fid=fopen(File,'r','l'); %open the felile filename. 
      fidmix=fread(fid,inf,'int16'); %read the file fid, one step by a int16, until the end (inf). 
      %Check the length to get the frames 
      NumFrame=length(fidmix)/(128*128);%Make sure the Matrix 
      ImStack=reshape(fidmix,128,128,NumFrame); %reshape the 1-dimmension array to 
a 256x256 matrix  
      





      h=figure; 
      hold on 
      set(h,'Name','Image sequence'); 
      %hold off 
      for i=1:NumFrame 
              ImMontg(:,:,1,i)=(mat2gray(ImStack(:,:,i)))'; 
              %M(i)=im2frame(gray2ind(Image),colormap); 
              imshow(ImMontg(:,:,1,i),'initialmagnification','fit'); 
              pause(1); 
      end 
      montage(ImMontg,'DisplayRange',[0.05 0.5]); 
 
else 
     
    errordlg('Not a valid RAW DATA file','Open file error') 
end 
%uicontrol('style','slider'); 








function Frame1_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 









function Frame2_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 














function Frame_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% -------------------------------------------------------------------- 
function Frame3_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame3 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 









function Frame4_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame4 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 










function Frame5_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame5 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 













function Frame6_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame6 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 










function Frame7_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame7 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 










function Frame8_Callback(hObject, eventdata, handles) 
% hObject    handle to Frame8 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 







guidata(hObject,handles)     
         
% -------------------------------------------------------------------- 
function SaveAll_Callback(hObject, eventdata, handles) 
% hObject    handle to SaveAll (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 





[filename, pathname]=uiputfile({'*.mat','MAT-file(*.mat)'},'Save as'); 
File=fullfile(pathname,filename); 
if isequal([filename,pathname],[0,0]) 
   return 
elseif ~isempty(strfind(filename,'.mat')) 
    try 
       ThData=handles.ThData; 
       SIData=handles.SIData; 
       SegMeanVal=handles.Seg_MeanVal; 
       SegUpLtRow=handles.Seg_UpLtRow; 
       SegHtMat=handles.Seg_HtMat; 
       NuSegMeanVal=handles.NuSeg_MeanVal; 
       NuSegUpLtRow=handles.NuSeg_UpLtRow; 
       NuSegThData=handles.NuSeg_ThData; 
       NuSegHtMat=handles.NuSeg_HtMat; 
       NuSegMarker=handles.NuSeg_Marker; 
       StdHtMat=handles.StdHtMat;     
        
   catch 
      errordlg('Make sure you have enough data to save!'); 
      return 
   end        
    save (File, 'ThData','SIData','SegUpLtRow','SegMeanVal',... 
        'SegHtMat','NuSegMeanVal','NuSegUpLtRow','NuSegHtMat',... 
        'NuSegThData','NuSegMarker','StdHtMat'); 
 
else 






function LoadData_Callback(hObject, eventdata, handles) 
% hObject    handle to LoadData (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
InputDir=uigetdir('C:\Documents and Settings\Yidong Yang\My Documents\Matlab 
Data',... 
    'Select directory containing data files'); 
FileList = dir(fullfile(InputDir,'/*.mat')); 

















%Fitting data for each cardiac area (Healthy,Adj,MI,Adj,Healthy) 
FitData=zeros(10,L); 




    %get the filename of the first file within the input directory 
    FileName{n,1}=FileList(n).name; 
    s=load(fullfile(InputDir,FileName{n,1})); 
    ThDataAll(:,n)=s.ThData; 
    SIDataAll(:,n)=s.SIData; 
    Seg_UpLtRowAll(:,n)=s.SegUpLtRow; 
    Seg_MeanValAll(:,n)=s.SegMeanVal; 
    Seg_HtMatAll(:,:,n)=s.SegHtMat; 
    NuSeg_UpLtRowAll(:,n)=s.NuSegUpLtRow; 
    NuSeg_MeanValAll(:,n)=s.NuSegMeanVal; 
    NuSeg_HtMatAll(:,:,n)=s.NuSegHtMat; 
    NuSeg_ThDataAll(:,n)=s.NuSegThData; 
    NuSeg_MarkerAll(:,n)=s.NuSegMarker; 
    StdHtMatAll(:,:,n)=s.StdHtMat; 
end 
 












    FitData(i,:)=FitData(i,:)*3.6;%convert to degree (360/100). 







%Here write all the necessary data to Excel 
[filename, pathname]=uiputfile('*.xls','Load data to Excel'); 
%If 'Cancel' was selected then return 
if isequal([filename,pathname],[0,0]) 
    return 
else 
    File=fullfile(pathname,filename); 
    %Write the filename into each row of spreadsheet 
    for i=1:1:5 
        xlswrite(File,FileName',i); 
    end 
    %1st write the thickness data 
    xlswrite(File,ThDataAll,1,'a2'); 
    %2nd write the SI data 
    xlswrite(File,SIDataAll,2,'a2'); 
    %3nd write the mean values of each partition in Uniform Segmentation 
    xlswrite(File,Seg_MeanValAll,3,'a2'); 
    %4th write the mean valuse of each partition in Non-uniform 
    %segmentation 
    xlswrite(File,NuSeg_MeanValAll,4,'a2'); 
    %5th write the data for each area (Healthy,Adj,MI,Adj,Healthy) 
    xlswrite(File,FitData,5,'a2'); 
end 

















function SaveStatistic_Callback(hObject, eventdata, handles) 
% hObject    handle to SaveStatistic (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 






%save and write all the data to files 
[filename, pathname]=uiputfile({'*.mat','MAT-file(*.mat)'},... 
    'Save all statistic data'); 
File=fullfile(pathname,filename); 
if isequal([filename,pathname],[0,0]) 
   return 
elseif ~isempty(strfind(filename,'.mat')) 
    try 
       SegHtMean=handles.SegHtMean; 
       SegHtStdev=handles.SegHtStdev; 
       NuSegHtMean=handles.NuSegHtMean; 
       NuSegHtStdev=handles.NuSegHtStdev; 
       StdHtMean=handles.StdHtMean; 
       StdHtStdev=handles.StdHtStdev; 
        
   catch 
      errordlg('Make sure you have enough data to save!'); 
      return 
   end        
    save (File, 'SegHtMean','SegHtStdev','StdHtMean','StdHtStdev',... 
        'NuSegHtMean','NuSegHtStdev'); 
 
else 
    errordlg('Please specify a file format from the list!'); 
end 
 
return; 
 
